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I Abstract  
During acute inflammation, polymorphonuclear neutrophils (PMN) are the first leukocytes to 
arrive at sites of injury. To maintain the polarised morphology during migration, molecules of 
the class II non-muscle myosins (NMII) are essential. In PMN, only one of the three in 
mammalian cells existing myosin heavy chains (Myh), namely Myh9, the heavy chain of 
NMIIA, is expressed. This study set out to unravel the functional impact of Myh9 on PMN 
trafficking in vitro and in vivo using genetic downregulation of Myh9 in mice. 
Treatment of murine bone marrow-derived PMN with pn-blebbistatin, a pharmacological 
inhibitor of NMII activity, revealed a dose-dependent impairment of migration velocity under 
flow conditions, accompanied by a change in morphology as well as reduced transmigratory 
capacity in vitro. As the complete knock-out of Myh9 in the hematopoietic system was lethal, 
Vav-iCre+/Myh9wt/fl (Myh9-cHet) mice with a significant reduction of Myh9 expression in 
PMN were used in the following experiments. During in vitro migration under flow 
conditions in 2D environment, reduction of Myh9 expression in Myh9-cHet PMN 
significantly diminished migration velocity and Euclidean distance compared to        
Vav-iCre-/Myh9wt/fl (control) PMN. Similarly, in vitro transmigration of Myh9-cHet PMN was 
reduced compared to control PMN. In addition, downregulation of Myh9 decreased PMN 
migration in confined 3D environment in vitro. Using STED nanoscopy, the underlying 
mechanisms causing the migration defect was evaluated and a dysregulation of F-actin 
dynamics upon Myh9 downregulation was discovered. In a model of acute peritonitis, 
reduced Myh9 expression in the hematopoietic system resulted in significantly diminished 
PMN recruitment in vivo. The induction of a sterile injury in the ear dermis of Myh9-cHet and 
control mice revealed a diminished extravasation as well as decreased interstitial migration 
velocity and Euclidean distance for PMN of Myh9-cHet mice compared to PMN of control 
mice. Three different models of bone marrow chimeric mice, namely wildtype mice carrying 
a wildtype hematopoietic system, wildtype mice carrying a Myh9-cHet hematopoietic system 
and wildtype mice carrying a hematopoietic system consisting of a 50:50 mixture of wildtype 
and Myh9-cHet cells, were generated. The induced peritonitis in these three models revealed a 
cell-intrinsic mechanism causing migration defects in PMN with reduced Myh9 expression. 
Next, Hoxb8-SCF cell-derived neutrophils were examined as a potential tool to study the 
molecular mechanism of PMN trafficking. In vitro assays comparing undifferentiated and 
differentiated Hoxb8-SCF cells with PMN demonstrated the typical segmentation of nuclei 
during differentiation towards PMN in Hoxb8-SCF cells, as well as the downregulation of 
progenitor markers and upregulation of PMN surface markers to similar levels found on 
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mature PMN. In functional in vitro assays reviewing integrin upregulation after stimulation, 
induction of adhesion as well as mechanotactic and chemotactic migration on 2D surfaces, 
Hoxb8-SCF cell-derived neutrophils demonstrated behaviour similar to murine bone marrow-
derived PMN. Hoxb8-SCF cells were generated from Vav-iCre+/Myh9wt/fl, Vav-iCre+/Myh9fl/fl 
and Vav-iCre-/Myh9fl/fl fetal liver progenitor cells, and expression of Myh9-EGFP in Hoxb8-
SCF cells with a Myh9 knock-down was able to rescue the Myh9-related migration defects in 
2D and 3D environment. Live cell imaging provided evidence that Myh9 localised in 
branching lamellipodia and in the uropod where it may enable fast PMN migration. In 
summary, the severe migration defects in vitro and in vivo upon reduction of Myh9 expression 
indicated a fundamental role of Myh9 for PMN trafficking in innate immunity. 
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II Zusammenfassung 
Während der akuten Entzündungsreaktion sind polymorphkernige neutrophile Granulozyten 
(PMN) die ersten Leukozyten, die in das entzündete Gewebe rekrutiert werden. Um während 
der Migration eine polarisierte Morphologie aufrecht zu erhalten, sind Moleküle der 
Nicht-Muskel-Myosine Klasse II (NMII) entscheidend. PMN besitzen nur eine der drei NMII-
Isoformen, die in Säugerzellen exprimiert werden. Der NMII-Proteinkomplex in PMN basiert 
auf der schweren Kette 9 (Myh9). In dieser Studie sollte mit Hilfe von genetischer 
Herunterregulation der Myh9-Proteinmenge der funktionelle Einfluss von Myh9 auf das 
Migrationsverhalten von murinen PMN in vitro und in vivo aufgeklärt werden.  
Zunächst wurde die Aktivität von NMII pharmakologisch mit dem Inhibitor pn-Blebbistatin 
gehemmt. Hierbei konnte nachgewiesen werden, dass die Migrationsgeschwindigkeit unter 
Flussbedingungen und die Morphologie während der Migration dosisabhängig beeinträchtigt 
wurden. Zusätzlich wurde eine verminderte Transmigrationsrate der pharmakologisch 
behandelten Zellen nachgewiesen. Im nächsten Schritt wurden Vav-iCre+/Myh9wt/fl 
(Myh9-cHet) Mäuse generiert, da ein Knock-out im hämatopoetischen System letal war. Diese 
Tiere wiesen eine signifikante Reduktion der Myh9-Expression in PMN auf. Die Analyse der 
Migration unter Flussbedingungen auf einer 2D-Oberfläche ergab eine verminderte 
Migrationsgeschwindigkeit sowie eine Senkung der Euklidischen Distanz in Myh9-cHet PMN 
im Vergleich zu Vav-iCre-/Myh9wt/fl (Kontroll)-PMN. Darüber hinaus waren die 
Transmigration und die Migration durch Engstellen im dreidimensionalen (3D) Raum in vitro 
von Myh9-cHet PMN, im Vergleich zu Kontroll-PMN, erniedrigt. STED-Nanoskopie lieferte 
Hinweise darauf, dass eine Dysregulation des F-Aktin Netzwerks aufgrund der Reduktion von 
Myh9 der Mechanismus für die Migrationsdefekte sein könnte. In einem Model der akuten 
Peritonitis führte die reduzierte Myh9-Expression im hämatopoetischen System zu einer stark 
gesenkten Anzahl an extravasierten PMN in den intraperitonealen Raum. Ein weiteres in vivo 
Model, das auf einer Laser-induzierten Verletzung am Ohr der Maus beruhte, bestätigte die 
Verringerung der Extravasation von PMN in Myh9-cHet Mäusen im Vergleich zu Kontroll-
Mäusen. Zusätzlich konnte dieses Model auch eine Herabsenkung der interstitiellen 
Migrationsfähigkeit der Myh9-cHet PMN im Vergleich zu Kontroll-PMN in vivo bestätigen. 
Unter Verwendung von drei verschiedenen Modellen von Knochenmarks-Chimären 
(1. Wildtyp-Mäuse mit einem hämatopoetischen System von Wildtyp-Tieren, 2. Wildtyp-
Mäuse mit einem hämatopoetischen System von Myh9-cHet-Tieren und 3. Wildtyp-Mäuse 
mit einem hämatopoetischen System bestehend aus einer 50:50 Mischung aus Wildtyp- und 
Myh9-cHet-Tieren) konnte im akuten Peritonitis-Modell gezeigt werden, dass ein 
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zell-intrinsischer Mechanismus für die Migrationsdefekte von Myh9-cHet PMN 
verantwortlich war. Im weiteren Verlauf dieser Studie wurden aus Hoxb8-SCF-Zellen 
differenzierte PMN hinsichtlich ihres Migrationsverhaltens charakterisiert. Hierzu wurden 
in vitro Untersuchungen durchgeführt, in denen undifferenzierte und differenzierte 
Hoxb8-SCF-Zellen mit PMN aus dem murinen Knochenmark verglichen wurden. Es zeigte 
sich, dass Hoxb8-SCF-Zellen im Laufe der Differenzierung zu PMN ihren Zellkern, wie für 
PMN typisch, segmentierten. Auch erfolgte währenddessen, eine Herunterregulierung von 
Vorläuferzell-Oberflächenmarkern und eine Hochregulation von PMN-Markern bis zu einem 
Level, das für reife PMN typisch ist. In funktionellen Untersuchungen, welche die Integrin-
Hochregulation nach Stimulation, die Induktion der Adhäsion, als auch die mechanotaktische 
und chemotaktische Migration auf 2D-Oberflächen überprüften, wurde ein Verhalten der 
differenzierten Hoxb8-SCF-Zellen sehr ähnlich zu PMN nachgewiesen. Hoxb8-SCF-Zellen 
wurden daraufhin aus den hämatopoetischen Vorläuferzellen der fötalen Leber von   
Vav-iCre-/Myh9fl/fl, Vav-iCre+/Myh9wt/fl und Vav-iCre+/Myh9fl/fl Embryos generiert. Die 
Myh9-abhängigen Migrationsdefekte in 2D und 3D konnten durch die Expression von 
EGFP-Myh9 in Hoxb8-SCF-Zellen mit einem Myh9 Knock-down, wieder aufgehoben 
werden. „Live Cell Imaging“ lieferte Hinweise darauf, dass Myh9 in verzweigten 
Lamellipodien und dem Uropod lokalisiert war, um möglicherweise eine schnelle Migration 
zu gewährleisten. Zusammenfassend weisen die schwerwiegenden Defekte in der Migration 
in vitro und in vivo bei verminderter Expression von Myh9 darauf hin, dass Myh9 für das 
Bewegungsverhalten von PMN in der angeborenen Immunreaktion eine fundamentale 
Bedeutung hat. 
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III Abbreviations 
2D 2-dimensional
3D 3-dimensional
ADM  Adhesion medium
ANOVA Analysis of variance
BDM 2,3 butanedione monoxine
bp Base pair 
BSA Bovine serum albumin
cfu Colony forming unit
cKO Conditional knock-out
ctrl Control
CXCL1 C-X-C motif chemokine 
d Days
DAMPs Damage-associated molecular patterns 
DFP Diisopropyl phosphofluoridate
dHoxb8 cells Hoxb8-SCF cell-derived neutrophils 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxid
DNA Deoxyribonucleic acid
EDTA Ethylenediamine-tetraacetic acid 
EGFP  Enhanced green fluorescent
ELC Essential light chain
ER Estrogen responsive element
FACS Fluorescence-activated cell sorting 
FC Flow cytometry 
FITC Fluorescein isothiocyanate
fwd Forward
GEFs Guanine exchange factors
GPCR G-protein coupled receptor
h Hours
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
het Heterozygous
HL-60 Human promyelocytic leukemia cells 
HPK1 Hematopoietic progenitor kinase-1 
i.p. Intraperitoneal
ICAM-1 Intercellular adhesion molecule-1 
IF Immune fluorescence
IgG Immunoglobulin G
IL Interleukin
LFA-1 Lymphocyte function-associated antigen-1 
LPS Lipopolysaccharide
m Murine
mAbp1 Mammalian actin binding protein 1  
Mac-1 Macrophage-1 antigen
min Minutes
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MLCK Myosin light chain kinase
MLCP Myosin light chain phosphatase
MPO Myeloperoxidase
Myh Myosin heavy chain
NADPH Nicotinamide adenine 
NETs Neutrophil extracellular traps
NMII Class II non-muscle myosin 
o.n. Over night
PAMP Pathogen-associated molecular pattern 
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PE Phycoerythrin
PECAM-1 Platelet/endothelial adhesion molecule-1 
PFA Paraformaldehyde
PI3K Phosphatidylinositol 3-kinase
PIP3 Phosphatidylinositol (3,4,5)‑triphosphate 
PKC Protein kinase
PMA Phorbol myristate acetate
PMN Polymorphonuclear neutrophils
pn-blebbistatin Para-nitro blebbistatin
PSGL-1 P-selectin glycoprotein ligand-1 
rev Reverse
RLC Regulatory light chain
rm Recombinant murine
ROCK Rho-associated protein kinase
ROS Reactive oxygen species
RPMI Roswell Park Memorial medium 
RT Room temperature
SCF Stem cell factor
SEM Standard error of the mean
Syk Spleen tyrosine kinase
TAE Tris base, acetic acid and EDTA 
TBS Tris buffered saline
TBST Tris buffered saline with Tween®20 
TNF-α Tumor necrosis factors-α
VCAM-1 Vascular cell adhesion molecule-1 
WB Western blot
wt Wildtype
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1 Introduction 
1.1 The acute inflammatory response 
Acute inflammation is the rapid response of a tissue to injury. It is usually of short duration, 
lasting only minutes to hours. John Hunter, an English surgeon in the 18th century was the 
first to realise that this response was generally beneficial for the host and that inflammation 
can be regarded as the first line of defence against injury1,2. This injury, often accompanied by 
cell death, can be provoked by biological (e.g. bacteria), chemical (e.g. acid burn) or physical 
(e.g. surgical trauma) insults3. Acute inflammation is characterised by the cardinal signs 
redness (rubor), increased heat (calor), swelling (tumor), pain (dolor), identified by the roman 
physician A.C. Celsus, and loss of function (functio laesa), later described by Galen of 
Pergamon. Most of these symptoms are caused by the two main components of the acute 
inflammatory response: the microcirculatory response including dilatation of arterioles for 
increased blood supply to the affected area, increased permeability of capillaries to allow 
exudation of plasma proteins, and the cellular response, which is characterised by the 
emigration of leukocytes, predominantly polymorphonuclear neutrophils (PMN), from the 
vasculature into the inflamed tissue4. The inflammatory processes allow the removal of the 
injurious agent and necrotic tissue, as well as the preparation for healing, finally leading to a 
complete resolution5. Under these circumstances, the tissue injury is self-limited and only 
mild fibrosis occurs. However, if the inflammatory processes cause further injury, a 
self-perpetuating inflammatory loop can be induced leading to chronic inflammation6,7. 
 
1.1.1 The role of PMN  
PMN are prominent members of the innate immune system and essential for an effective 
immune response 8,9. The first to describe the relevance of these phagocytic cells for the 
elimination of foreign particles such as bacteria was the Russian zoologist E. Metschnikow in 
the late 19th century10,11. After release from the bone marrow, PMN circulate in the blood of 
mice with a half-life of approximately 12 hours12. In the human circulation, a similar life-span 
of PMN was identified using ex vivo labelling of PMN13. A more recent study using in vivo 
labelling, suggests a longer average circulation time of 5 days12. Under steady-state 
conditions, clearing of PMN occurs via apoptosis and engulfment by macrophages in the 
liver, spleen, and bone marrow 14,15 Very recent studies report homeostatic infiltration of 
PMN in naive tissues with the potential to support organ function16 and describe a circadian 
rhythm protein as internal timer in PMN ensuring both, vascular protection and immune 
defence17. During acute inflammation, PMN are the first leukocytes to arrive at the site of 
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injury through rapid recruitment from the blood stream into the inflamed tissue9. This process 
is initiated by tissue resident macrophages or dendritic cells, which recognize components of 
bacteria or other pathogen associated molecular pattern (PAMPs) via specific pattern-
recognition receptors such as members of the toll-like receptor family18,19. Damage associated 
molecular patterns (DAMPs) on the other hand, indicate tissue damage and can also be 
detected by these cell types20. DAMPs are mostly intracellular or nuclear proteins released 
during the cell death of damaged cells21. Subsequently, pro-inflammatory mediators like 
tumour necrosis factor α (TNFα) or interleukin-1β (IL-1β) are released, resulting in the 
activation of endothelial cells in the adjacent vessel21-23. As a consequence of their activation, 
endothelial cells upregulate adhesion molecules on the luminal side of the vessel, crucial for 
the recruitment and the extravasation of PMN9,24,25. Upon arrival in the interstitial tissue, 
PMN have been observed to swarm around a wounded area26,27. Initially, individual PMN, 
located close to the damage, migrate via chemotaxis towards the site of injury. The release of 
the lipid mediator leukotriene B4 amplifies the local signals and enhances the radius for PMN 
recruitment resulting in amplified chemotaxis of PMN, consequently leading to PMN 
clustering around the site of inflammation27,28.  
Once the PMN arrive at the site of inflammation, they can exert anti-microbial functions. The 
phagocytosis of C3b or immunoglobulin G (IgG) opsonised particles occurs via binding to 
CD11b or Fcγ receptors on the surface of PMN29. The PMN build a phagosome by enclosing 
the particle with the cell membrane. Subsequently, a phagolysosome develops by fusion of the 
phagosome with lysosomes which contain hydrolytic enzymes and calcium dependent 
NADPH-oxidase. NADPH-oxidases produces reactive oxygen species (ROS) through 
consumption of oxygen, a process known as respiratory burst30. Along with the oxidative 
active hypochlorous acid, built by the myeloperoxidase (MPO) catalysed process of chloride 
oxidation in the presence of hydrogen peroxide, ROS are crucial for the elimination of the 
engulfed pathogens31,32. Additionally, PMN store multiple proteases like neutrophil elastase, 
cathepsin G, or matrix metalloproteases and antimicrobial peptides like MPO, defensines and 
lysozyme in their granules33,34. These granules are either fused with the phagolysosomes or 
their content can be secreted into the extracellular space to eliminate pathogens33. 
Furthermore, PMN contribute to the elimination of pathogens through neutrophil extracellular 
traps (NET) formation. Specifically, PMN eject de-condensated chromatin decorated with 
proteins such as neutrophil elastase and MPO. The pathogens then become trapped and 
immobilised in the network and are potentially killed or damaged by the antimicrobial 
peptides and enzymes attached to the chromatin DNA35,36. The clearance of PMN from the 
  Introduction 
14 
 
site of inflammation had been thought to occur by macrophages and monocytes in the tissue. 
However, recent studies have observed that PMN clear debris, perform essential repair 
functions, migrate away from the site of infection and are efficiently cleared from the tissue 
also in the absence of monocytes and macrophages37-39. Therefore, it is hypothesised that they 
may re-enter the blood stream. However, until today, no completely reverse-transmigrated 
PMN has been visualized and the physiological relevance remains unclear40. Despite their role 
as professional phagocytes, the presence of PMN at sites of inflammation is also crucial for 
effective recruitment of monocytes and immune cells from the adaptive immune system41-44, 
along with the re-creation of new structures in the damaged tissue by collagen deposition, 
leading to healing27,45.  
 
1.1.2 The PMN recruitment cascade  
The above introduced recruitment of PMN from the blood stream into the inflamed tissue 
follows a tightly regulated, consecutive multistep cascade. This includes capturing, fast and 
slow rolling, firm adhesion, adhesion strengthening, spreading, intraluminal crawling, 
transmigration, abluminal crawling, and interstitial migration to sites of 
inflammation8,46 (Fig. 1).  
 
 
Figure 1. The PMN recruiting cascade. The recruiting of PMN during acute inflammation is 
arranged into consecutive steps. These steps are termed capturing, rolling, arrest, firm 
adhesion and adhesion strengthening, spreading, intraluminal crawling, transmigration, 
abluminal crawling and interstitial migration. At the site of inflammation PMN can fulfil their 
function as professional phagocytes to eliminate the source of inflammation. Despite the 
process of slow rolling, transmigration and interstitial migration, the other processes depend 
on the presence of β2 integrins (modified from Schymeinsky et al. 201147). 
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At first, freely circulating PMN in the blood get close to the inflamed vessel wall in a process 
called margination and are captured by the endothelial cells. The subsequent rolling is 
mediated by adhesion molecules of the selectin family presented by the endothelial cell and 
selectin ligands, such as the P-selectin glycoprotein ligand-1 (PSGL-1) on the PMN48,49. 
Endothelial cells express two different selectins, P-selectin and E-selectin. In contrast to 
P-selectin, E-selectin enables slower rolling velocities, facilitating the recruiting of PMN into 
the underlying tissue50. However, its availability on the endothelial cell surface is delayed due 
to de-novo synthesis upon stimulation. Conversely, P-selectin is stored in specific vesicles 
like the Weibel-Palade bodies in endothelial cells and can be presented on the endothelial cell 
surface within a few minutes after stimulation51-53. Importantly, the process of slow rolling 
requires additional support of β2 integrins, presented by the PMN, and their interaction with 
the intercellular adhesion molecule-1 (ICAM-1), which is expressed on the cell surface of 
endothelial cells54,55. The interaction with PSGL-1 triggers a signalling cascade into the PMN 
resulting in a switch of the β2 integrin from the bend, inactive E(-) H(-) conformation toward 
a partially activated β2 integrin with intermediate affinity characterised by an extended (E+) 
conformation and a closed headpiece (H-), defined as E(+) H(-)56-58. For the transition into the 
high-affinity conformation, which is necessary for the firm adhesion of the PMN on the 
endothelium, further stimuli, originating from the endothelial cells, are required. The binding 
of the chemokine CXCL1 to its receptor, the G-protein coupled receptor (GPCR) CXCR2 is 
one example that leads to the full activation of the β2 integrin characterised by an extended 
conformation and an open head domain, E(+) H(+)59,60. This process is termed inside-out 
signalling61. The extension of the head domain away from the plasma membrane requires the 
binding of the adapter protein Talin-1 on the cytoplasmic tail of the CD18 subunit of the β2 
integrin62,63. For the opening of the headpiece by dissociation of the two β2 integrin subunits, 
the adaptor protein kindlin-3 is crucial63,64. PMN have been found to influence their activation 
state through an endogenous anti-inflammatory mechanism by binding their β2 integrin to 
ICAM-1 in cis leading to stabilisation of the bend conformation with an open headpiece, 
E(-) H(+) and inhibition of adhesion65. Post-adhesion events like adhesion strengthening and 
spreading of the PMN are further promoted through outside-in signalling from the β2 integrin 
into the cell upon binding to its ligand ICAM-166. In the case of ligand binding in trans, 
signalling events lead to a reorganisation of the cytoskeleton, enabling spreading, and an 
increase in integrin-ligand interactions, strengthening the bond between the PMN and the 
endothelium8. Upon establishment of polarity, PMN migrate in an β2 integrin-dependent 
fashion along the endothelium to find a suitable spot for extravasation into the inflamed 
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tissue67,68. The transmigration through the endothelium can occur via the paracellular or the 
transcellular route69 and is dependent on the smooth and effective execution of the complex 
communication and interaction processes between endothelial cells and PMN70. In endothelial 
cells, the engagement by PMN triggers extensive dynamic modifications of the actin 
cytoskeleton, including the induction of membrane structures around adherent PMN, so called 
transmigratory cups, that support the transmigration of PMN71,72. Upon successful 
transmigration through the endothelial cell layer, PMN pass the basal membrane of the blood 
vessel and migrate along pericytes in an β2 integrin-dependent fashion along the abluminal 
side of the blood vessel73-76. To finally reach the site of inflammation, PMN migrate in a 
directed fashion through the fibrillary network of the interstitial space77-79. With the 
recruitment completed, PMN can exert their defence functions in the tissue.  
A proper operating PMN recruitment to the site of inflammation is crucial for humans and 
mice. Misfunctions in this process lead to insufficient immune responses and recurring 
infections as described in patients with leukocyte adhesion deficiency (LAD) I – IV, caused 
by mutations of CD18, malfunction of selectin ligands, a mutation of kindlin-3 preventing the 
E(+) (H+) β2 integrin conformation, or a dominant-negative mutation in Rac280-83.  
 
1.2 The mechanisms of PMN migration  
The mobility of cells is fundamental for correct functioning of the body for any organism 
throughout its lifespan. During embryonic and postnatal development, various cell types need 
to migrate to their destination to organise organs and tissues for proper functionality. In the 
process of angiogenesis, cells need to migrate to form new vessels. In the case of 
inflammation, cells must be able to migrate to the lesion to eliminate the source of 
inflammation and to progress wound healing and tissue regeneration84. Two characteristic 
modes of migration can be distinguished: mesenchymal and amoeboid migration. Fibroblasts, 
smooth muscle cells, endothelial and epithelial cells have been described to perform 
mesenchymal migration, whereas most blood cells migrate in an amoeboid fashion85. 
Epithelial cancer cells, after epithelial-to-mesenchymal transition, can migrate with a 
mesenchymal phenotype and some even adopt amoeboid migration86. Cells migrating in the 
mesenchymal mode display an elongated spindle-like shape with one or often more leading 
pseudopods. The process is mainly driven by actin-rich protrusions promoted by the small 
GTPases Rac and Cdc42. The cells show strong adhesive interactions with the extracellular 
matrix via integrins. Stress fibres and focal adhesions are employed to generate traction force 
and to recruit extracellular matrix degrading proteolytic enzymes used to generate a path for 
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migration. In contrast, amoeboid migrating cells display a rounder morphology with usually 
one single protrusion at the leading edge. They are highly deformable and undergo constant 
shape changes. Their strong signalling via the Rho/ROCK pathway and their contractile actin 
cortex enables these cells to squeeze through gaps. Hence, the proteolytic activity in 
amoeboid migrating cells is low or absent. In combination with lower substrate adhesiveness 
compared to mesenchymal migrating cells, amoeboid migrating cells display a much higher 
migration speed and can react faster to changes in chemotactic stimuli in   
their environment84-86.  
PMN belong to the group of cells that employ amoeboid migration. Specifically, actin 
polymerization is essential for the protrusive formation of the leading edge of migrating cells, 
whereas contraction of the acto-myosin network assists movement by retracting the back of 
the cell87,88. For the cytoskeletal dynamics and directed migration, the sensing of 
chemoattractant gradients and the intrinsic ability of the cells to establish a polarised state are 
fundamental. Polarisation is induced by binding of chemoattractants to GPCRs, which are 
seven-transmembrane domain receptors and are evenly distributed throughout the cell 
membrane89. PMN can react to very shallow chemoattractant gradients in their environment 
by internal signalling amplification leading to a much higher intracellular asymmetry 
compared to the small extracellular asymmetry90. Upon activation, the GPCR-interacting 
heterotrimeric G-protein subunits Gα and Gβγ dissociate from the receptor resulting in 
downstream activation of effector proteins including Ras, RhoA, protein kinase Cβ (PKCβ), 
adenylyl cyclase or phospholipase C (Fig. 2)91. For the establishment of a leading edge, the 
phosphatidylinositol 3-kinase (PI3K) becomes directly activated by the Gβγ subunit. This 
results in activation of phosphatidylinositol (3,4,5) triphosphate (PIP3) and Rac-guanine 
exchange factors (GEFs), stimulating the activity of the small GTPase Rac. Together with 
Cdc42, another small GTPase, Rac is crucial for stabilisation of the leading edge and actin 
polymerization to push the cell forward46,92,93. For the formation of a trailing edge, the small 
GTPas RhoA becomes enriched and activated at the uropod upon release from its inhibitor 
moesin94. The PTEN phosphatase, which acts negatively on PI3K and PIP3 is simultaneously 
recruited to the rear of the cell in a RhoA dependent manner95. RhoA activates the myosin 
light chain kinase ROCK which drives contraction of the rear96,97. A regulatory feedback loop 
between the effector molecules acting at the leading and the trailing edge of the cell ultimately 
secures actin polymerization and acto-myosin contractility in a spatiotemporal manner92,94. 
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Figure 2. Signalling during PMN 
polarisation. Upon GPCR signalling, the 
dissociated subunit Gβγ activates Rac-
GEFs or PI3K producing PIP3. A positive 
feedback loop in the front of the cell 
activating Rac and inhibiting Rho 
signalling results in active actin 
polymerization that pushes the cell 
forward. The back of the cell is 
characterised by RhoA signalling and 
PTEN recruitment which results in acto-
myosin contractile forces and inhibition 
of Rac signalling at the back of the cell 
(adapted from Gambardella et al. 201389). 
 
 
During their recruitment to sites of inflammation, PMN must migrate in environments with 
different requirements. To meet these requirements, PMN possess highly specialized 
molecular mechanisms. It has been demonstrated that integrins are crucial in mediating 
adhesion on surfaces and enabling force transmission in this two-dimensional (2D) 
environment8,98. For example, murine PMN lacking the β2 integrin lymphocyte function-
associated antigen-1 (LFA-1, CD11a/CD18) have severely impaired adhesion in inflamed 
postcapillary venules, whereas murine PMN with a deletion of macrophage-1 antigen (Mac-1, 
CD11b/CD18) are able to induce adhesion but are not able to migrate along the endothelial 
cells in vivo67. Also, abluminal crawling of PMN along the pericyte layer has been found to be 
β2 integrin dependent in mice in vivo75. Locally applied blocking antibodies against 
β2 integrins hinder the interaction of ICAM-1 expressing pericytes with LFA-1 and Mac-1 
expressing PMN, resulting in reduced migration speed and track length of PMN migrating 
along pericytes in mice75. Recently, an unexpected role for integrin-mediated adhesion has 
been discovered using a mouse model of sterile injury in the ear skin dermis and PMN 
deficient for β2 integrins or talin, resulting in PMN lacking the intermediate and high-affinity 
conformation of integrins. Here, the deficient PMN accumulate at the transition zone between 
three-dimensional (3D) fibrillar interstitium and the cell-rich collagen-free wound zone and 
fail in contrast to wildtype PMN to accumulate in the centre of the wound, suggesting that 
β2 integrins are in involved in movement within cell clusters27,77.  
Analysis of murine PMN migration in 3D collagen gels in vitro and in the interstitium of the 
mouse ear in vivo demonstrate integrin-independent migration in this environment: Talin or 
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β2 integrin deficient PMN as well as PMNs treated with β2 integrin function-blocking 
antibodies migrate as efficiently as control PMN in fibrillar 3D environment77,87,99. Forward 
movement under these circumstances is solely based on the two force generating principles of 
plasma membrane expansion via actin polymerization at the front of the cell and acto-myosin 
based contraction at the rear of the cell87,88,100. Hence, the fibrillar environment of the 
intersitium or in vitro collagen networks provide sufficient traction force transmission from 
the PMN to the environment to ensure proper cell movement even without anchoring 
integrins. 
In vivo, PMN need to adhere and migrate under shear stress provoked by the blood stream. 
PMN migrate in the direction of the blood flow, but also against and perpendicular to the 
direction of flow until they reach a suitable extravasation site9,67. Here, β2 integrins in their 
high affinity conformation are crucial for resistance against shear stress59,101. In addition, 
several other proteins have been identified with specific importance under flow conditions. 
This means that they are dispensable for migration under static conditions, yet crucial for 
effective migration under flow conditions. In this context, Vav1, a GEF for the Rho family 
GTPases Rac and Cdc42, is important for the organisation of the actin cytoskeleton during 
leukocyte polarisation and migration. Murine PMN which lack Vav1 have been shown to lose 
their ability to migrate against and perpendicular to the direction of flow102. The mammalian 
actin-binding protein 1 (mAbp1) becomes activated by the nonreceptor spleen tyrosine kinase 
Syk during the process of slow rolling103,104. In vitro and in vivo studies in mice have 
demonstrated impaired adhesion, intraluminal crawling and extravasation of mAbp1 deficient 
PMN and suggest a role for mAbp1 in stabilising the high affinity conformation of 
β2 integrins104. Additionally, the mAbp1 interacting protein hematopoietic progenitor 
kinase (HPK)1 has been found to be required for CXCL1-induced high-affinity LFA-1, but 
dispensable for Mac-1 affinity regulation. HPK1-deficient murine PMN fail to adhere and 
migrate properly under flow conditions in vitro and in vivo105. Furthermore, the RhoA-
specific GEF-H1 has been demonstrated to be crucial for adhesion, spreading and migration 
exclusively under shear stress conditions. Shear stress promotes its activation through 
dissociation from the microtubules and its relocation to the uropod of the cell. Here, it exerts 
its function in regulating the activity of RhoA, presenting a link between mechanosensing and 
Rho signalling106. In summary, PMN adapt their highly specific molecular mechanisms and 
specialized signalling pathways to the requirements of a changing environment during their 
recruitment from the blood stream to the site of inflammation. 
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1.3 The myosin superfamily  
Myosins are a large and diverse superfamily of actin-based molecular motors107. Due to their 
ability to convert chemical energy through ATP hydrolysis into mechanical energy they are 
classified as mechanochemical enzymes108. In contrast to kinesins and dyneins which utilise 
microtubules for transport, myosins move along actin filaments108. All myosins are composed 
of at least one heavy chain and several light chains. The heavy chain is organised into three 
domains with different structures and functions109. The most conserved domain is the globular 
head domain containing the ATP- and actin binding sites. The α-helical neck region lies 
adjacent to the head domain and associates with the light chains regulating the activity of the 
head domain. The tail domain contains binding sites that determine the specific activities of 
that particular myosin and displays the most sequence divergence enabling the discrimination 
between myosin subgroups or isoforms110. The class II myosin subfamily has the most 
members and includes the first described myosin, the skeletal muscle myosin. In vertebrates 
there are over 15 different isoforms known, each identified by a different heavy chain107. The 
skeletal muscle myosin, along with cardiac and smooth muscle myosin as well as non-muscle 
myosin are also known as conventional myosins111. All other classes are termed 
unconventional. Along these over 17 classes, class I myosins are the most abundant group112. 
The structure of class I and II myosin is strikingly different and is reflecting their specific 
functions. Class II myosin is known to be involved in generating force for contraction, 
whereas class I myosin is proposed to play various cellular roles related to membrane 
dynamics and trafficking111. Class II myosin molecules are hexamers composed of a heavy 
chain dimer and two pairs of myosin light chains113. The α-helical sequences in the tails of the 
heavy chains allow the association of the two monomers to a rod-like coiled-coil structure. 
Due to the lack of this α-helical sequence in class I myosin, these molecules exist as 
monomers. Between class I and II myosin, the type and number of light chains bound to the 
neck region differs, with one calmodulin light chain for class I myosin and two different light 
chains, termed essential and regulatory light chain, for class II myosin108. Importantly, all 
eukaryotic cells contain class II non-muscle myosin molecules resembling their muscle 
counter-parts with respect to structure and function. However, their regulation is 
fundamentally different to skeletal and cardiac muscle myosin. The latter are primary 
regulated through a set of actin-associated proteins named troponin and tropomyosin, whereas 
class II non-muscle myosin is regulated by phosphorylation of one of the light chains, termed 
regulatory light chain (RLC), allowing them to respond to numerous signals from outside and 
inside the cell114,115. 
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1.3.1 Class II non-muscle myosin 
In mammalian cells, there are three different genes for class II non-muscle myosin (NMII), 
located at three different chromosomes in humans and mice. These genes encode for the 
heavy chain of NMII determining the NMII isoform. Deletion of the specific heavy chain 
results in the loss of that NMII isoform. The heavy chain gene Myh9 encodes for NMIIA, 
Myh10 for NMIIB and Myh14 for NMIIC. Myh10 and Myh14 have been shown to undergo 
alternative splicing whereas for Myh9 only one mRNA variant has been reported116. The three 
heavy chain isoforms display around 64–89% sequence similarity but have different actin-
activated Mg2+-ATPase activities and duty ratios, meaning the fraction of time that the 
myosin motor is bound to an actin filament116.  
The most unique characteristic of class II myosin and therefore also of NMII, is the ability to 
form filaments via self-association of the rod-like coiled-coil α-helical tail of two or multiple 
heavy chains. These myosin filaments can link actin filaments together into thick bundles 
forming cellular structures such as stress fibres117,118. The formation of an acto-myosin 
filament occurs in consecutive steps119: In the absence of regulatory light chain (RLC) 
phosphorylation, head-to-tail interaction of the heavy chain stabilises a compact, auto-
inhibitory, and assembly incompetent conformation (Fig. 3A). Upon RLC phosphorylation, 
unfolding of the tail promotes the assembly competent, extended conformation (Fig. 3B). This 
conversion to the extended conformation also triggers the Mg2+-ATPase activity of the motor 
and enables the assembly into bipolar filaments (Fig. 3C). This filament assembly relies on 
the presence of C-terminal structures of the heavy chain tail which contain assembly-
competent domains and the non-helical tail and can be controlled by phosphorylation119. For 
the formation of these bipolar filaments, class II myosin monomers have to interact both 
parallel and anti-parallel resulting in a central bare zone which is not populated by motor 
domains and is designed to pull actin filaments towards the centre120. Interestingly, NMIIC 
has been found to have a longer bare zone and narrower filaments than NMIIA and B, 
indicating that NMIIC filaments incorporate less molecules121. The composition of these 
myosin filaments can be homotypic and, at least between NMIIA and B, heterotypic. In cell 
regions with predominantly NMIIA or NMIIB, homotypic filaments are dominant, in cell 
regions with colocalisation of NMIIA and NMIIB heterotypic filaments prevail122. In the final 
step during the generation of an acto-myosin filament, the bipolar NMII filaments link F-actin 
together enabling the cell to generate force (Fig. 3D). Force generation for contraction occurs 
through the sliding movement of the motor domains of the myosin filaments along and within 
the actin filaments. 
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Figure 3. Assembly of class II non-muscle myosin (NMII) and acto-myosin filaments. 
The NMII heavy chain is shown in black, the associated essential and regulalatory light chains 
(ELC and RLC) are shown in grey and blue. The globular head domain contains actin-binding 
regions and the enzymatic Mg2+-ATPase motor domain. (A) In the absence of RLC 
phosphorylation, NMII forms a compact molecule through a head-to-tail interaction that is 
unable to associate with other NM II dimers. (B) Phosphorylation of the RLC promotes 
unfolding of the tail to the assembly competent, extended conformation. (C) The conversion 
to the extended conformation triggers the Mg2+-ATPase activity and NMII assembly into 
bipolar filaments through both parallel and anti-parallel interactions between the coiled-coil 
tail domains of NMII monomeres. (D) The bipolar NMII filaments bind to F-actin through 
their head domains, linking actin filaments together into thick bundles (lower left side). The 
ATPase activity of the NMII head enables a conformational change that can move the actin 
filaments in an anti-parallel manner (adapted from Dulyaninova et al. 2013119). 
 
For decades, researches have tried to identify the specific expression pattern, subcellular 
localisations and functions of the three NMII isoforms NMIIA, B and C. Immunofluorescence 
staining, protein expression analysis by western blot and mass spectrometry, quantification of 
mRNA levels and several mouse models have provided valuable insights, however, it also has 
become clear that the functions of the NMII isoforms differ between cell types, depending on 
the combination, distribution and amount of the particular isoforms116,123-127: Mice ablated for 
Myh9 fail to develop a proper visceral endoderm and die by E7.5. These mice show defects in 
cell-cell adhesion by loss of proper E-cadherin and E-catenin localisation within cells126. 
Interestingly, the expression of Myh10 or Myh14 under the Myh9 promotor rescues survival 
beyond organogenesis but mice show major defects in placental development through lack of 
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foetal blood vessels in the labyrinthine layer, the interface for gas and nutrient exchange 
between the embryo and the mother124,128. These observations fit together with the widespread 
expression of Myh9 in embryonic tissues and the specific expression of Myh9 in the 
vasculature of the brain and the inner ear, in epithelial cells in the developing intestine and in 
non-myocytes in the heart. In adult organs, Myh9 is still absent in mature cardiac myocytes, 
expressed at low levels in the heart, and is the most abundant isoform in the spleen116,123,124. 
The knock-out of Myh10 in mice causes embryonic lethality by E14.5 due to abnormalities in 
the heart, with defects in cardiac myocyte cytokinesis and karyokinesis120,122. Moreover, the 
embryos show malformations in the hippocampus, which can be partly explained by defects 
in neuron migration in reaching their destination in the developing brain127,129,130. Myh9 
expression under the Myh10 promotor can partly rescue the defects in brain development, 
however the cardiac defects remain124,131. The expression pattern of Myh10 during embryonic 
development and in adult organs corresponds well with these findings in Myh10 knock-out 
mice: Myh10 is the abundant isoform expressed in neuroepithelial cells and neurons, 
mesenchymal epithelial cells in the inner ear, serosal cells in the intestine, the parenchymal 
cells in the lung and in ventricular cardiac myocytes. In the adult murine and human 
organism, Myh10, is most strongly expressed in the brain and mature cardiac 
myocytes116,124,132,133. The generation of Myh14 knock-out mice has revealed no obvious 
phenotype. Only in combination with reduced Myh10, defects have been identified, including 
impaired cell division of ventricular myocytes. This defect causes a marked reduction in the 
number of cardiac myocytes in the hearts of the embryo, as well as embryonic lethality at 
E14.5. A compensatory interaction between Myh10 and Myh14 in cardiac myocytes has 
therefore been suggested111,116,123. The observations in these mice are in line with the 
expression pattern of Myh14 in embryonic and adult tissues. Here, no Myh14 has been found 
in the embryo before E11.5. During later embryonic development, Myh14 is detectable in the 
pituitary of the brain, in the sensory cells of the cochlea in the inner ear, at the apical boarders 
of epithelial cells in the intestine, in airway epithelial cells in the lung, and in ventricular 
cardiac myocytes116,124,134. In adult tissue, only in the lung Myh14 can be found in a 
measurable amount. Here, a third of the total NMII protein is Myh14123.  
In summary, these findings suggest overlapping functions, as well as specific, 
non-compensable functional roles of the three NMII isoforms. In most cell types the distinct 
roles of the single isoforms is not completely understood, but a fundamental role for NMII for 
cytokinesis in cell division, substrate adhesion and cell-cell adhesion, as well as mediating 
cell shape change, polarisation, and migration is indisputable107,118,135-141. Several examples 
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for the role of NMII in cell division have been described. For instance, in HeLa cells and 
other dividing epithelial cells Myh9 and Myh10 locates to the cleavage furrow122,125. In 
addition, downregulation of Myh10 in COS-7 cells leads to reduced proliferation and 
enhanced percentage of poly-nucleated cells142. Downregulation of Myh10 in megakaryocytes 
also leads to polyploid cells as only Myh10 but not Myh9 locates to the cleavage furrow 
during cell division143. Finally, in hematopoietic progenitor cells, inhibition of NMII causes 
cytokinesis-associated cell death144. 
 
1.3.2 Myh9 - a class II non-muscle myosin heavy chain  
In most mammalian cell types all three isoforms, Myh9, Myh10 and Myh14, are 
simultaneously expressed. In hematopoietic cells, Myh9 is the dominant heavy chain for 
NMII125,145. For proper function of the NMIIA, with Myh9 as its heavy chain, the 
phosphorylation of the RLC is required. Several kinases have been reported to phosphorylate 
the RLC of NMIIA. In PMN, one of the few cell types in the body solely expressing Myh9 
and the leukocytes with the highest expression of Myh9125, three kinases involved in RLC 
phosphorylation have been described. The Ca2+-calmodulin activated myosin light chain 
(MLC) kinase (MLCK) and the RhoA controlled Rho-associated, coiled coil-containing 
kinase (ROCK), phosphorylate the RLC at Ser19 and Thr18, whereas the protein kinase C 
(PKC) targets Ser1 and 2 and Thr993,146,147. On the other site, myosin light chain phosphatase 
(MLCP) has been found to dephosphorylate the RLC119 and it plays a role in breaking 
symmetry in the process of polarisation in PMN by attractant-induced local inactivation of 
moesin, resolving the inhibition of the small GTPases Rac, Rho, and Cdc4294. In migrating T 
cells, MLCK and ROCK have been found to be spatially segregated, with MLCK mainly to 
the leading edge and ROCK enriched at the trailing edge. Here, inhibition of calmodulin leads 
to the retraction of the front of the cell, whereas inhibition of ROCK prevents the detachment 
of the trailing edge96. This supports the concept that cycling activity levels of MLCK and 
MLCP at the leading edge, and ROCK and MLCP at the sides and the trailing edge of the cell, 
result in locally controlled phosphorylated MLC levels, enabling the cell to orchestrate the 
building of protrusions, new and transient adhesion sites as well as directional migration148. 
The role of the RLC kinase PKC is not completely understood and seems to vary between cell 
types and environments. For instance, inhibition of PKCβII in PMN responding to 
chemoattractant stimulation causes severe tail retraction defects. Non-inhibited PKCβII 
translocates transiently to the plasma membrane, where it activates adenylyl cyclase 9 to 
induce cAMP production which results in downstream RLC phosphorylation91. In fibroblasts, 
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direct phosphorylation of the RLC by PKC decreases myosin activity through access 
restriction of MLCK to the RLC, resulting in a reorganisation of acto-myosin filaments149. 
Furthermore, PKCβ has been found to phosphorylate the heavy chain Myh9 at Ser1916 near 
the C-terminal end of the coiled-coil region in human platelets and T cells119,150,151.  
In line with this, there is emerging evidence for a pivotal role of the tail domain of the heavy 
chain, for controlling subcellular distribution of Myh9 and NMII filament formation119. 
Deletion studies involving the uncoiled tailpiece of the coiled-coil rod domain of the heavy 
chain have demonstrated its importance for functional relocation of the molecule: In COS-7 
cells, tailpiece deleted Myh9 is not able to colocalise with the cortical F-actin and remains 
homogenously distributed in the cytoplasm152. In natural killer cells, tailpiece deleted Myh9 
fails to associate with cytotoxic granules and prevents the secretion of perforin containing 
cytotoxic granules. Moreover, the phosphorylation at Ser1943 of Myh9 is crucial for the 
association between Myh9 and the cytotoxic granules153. In mast cells, the onset of 
degranulation has been demonstrated to be associated with phosphorylation of Myh9 at 
Ser1916154. In a human epithelial cell line, swapping of the C-terminal amino acids 179–190 
between Myh9 and Myh10 inverts the distinct distribution pattern of these two isoforms 
during migration136. Moreover, in U2O3 epithelial cells, the Myh9 tail is phosphorylated at 
Ser1916 by PKCβII upon integrin binding and subsequent Rac-1 activation. This has been 
described to be essential for recruitment of Myh9 to focal adhesions and their maturation155.  
The mammalian α-kinase transient receptor potential melastatin 7 (TRPM7) has been 
identified to phosphorylate human and murine Myh9 at Thr1800, Ser1803 and Ser1808152. In 
COS-7 fibroblasts, mutation of TRPM7 phosphorylation sites to phospho-mimetics reduces 
its incorporation into the acto-myosin cytoskeleton and results in its relocalisation away from 
the cell cortex152. In MDA-MB-231 breast cancer cells, casein kinase II (CKII) has been 
found to phosphorylate Myh9 at Ser1943119. This phosphorylation is associated with reduced 
NMIIA filament assembly156. A S1943 phospho-mimetic mutant increased migration, whereas 
a S1943 non-phosphorylable mutation caused over-assembly of NMIIA during spreading 
inhibiting cell migration157.  
Cell specific genetic approaches using mouse models have enabled the elucidation of NMII 
isotype specific functions such as the migration of immune cells. Cell specific Myh9 
knock-outs have been reported for T cells, dendritic cells, and platelets. In T cells, Myh9 is 
accumulated at the rear of transmigrating T cells which is crucial to squeeze the nucleus 
through sites of constriction158. In vivo, Myh9 conditional knock-out in T cells impairs the 
turnover of adhesion sites, resulting in increased adhesion and impaired interstitial 
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migration159. In addition, Myh9 has been found to be important for the disassembly of binding 
between LFA-1 and the ICAM-1, and retraction of the membrane at the rear of the T cell160. 
Using mass spectrometry, immunoprecipitation and confocal microscopy, an association 
between the C-terminal end of chemokine receptor CXCR4 and Myh9 has been described in 
T cells, suggesting a mechano-signalling mechanism with a biochemical association between 
chemokine receptors and motor proteins161. Other studies have implied that Myh9 serves as a 
mechanical link between LFA-1 and the cytoskeleton potentially influencing the activation 
state of LFA-1 in T cells162,163. For the functionality of the adaptive immune response, T cells 
interact with antigen-presenting cells via the immunological synapse. Myh9 has been found to 
be recruited to the immunological synapse and to be an essential participant in the formation 
and persistence of the immunological synapse and TCR signalling164,165. In dendritic cells, 
tight spatiotemporal regulation of Myh9 has been demonstrated to be crucial for migration 
and antigen capture166. Mice with an ablation of Myh9 in megakaryocytes display 
macrothrombocytopenia with a strong increase in bleeding time167. Thrombus growth, 
organisation, and stability is impaired, because of the important role of Myh9 for platelet 
contractility and outside-in signalling. Recently, it has been reported that Myh9 is crucial for 
platelet migration to fulfil their role as mechano-scavengers, binding and collecting bacteria 
as well as fibrinogen168. Knock-down studies targeting Myh9 by RNA interference provide 
evidence that Myh9 is required in B cells for B cell receptor (BCR)-driven antigen 
presentation by participating in the formation of MHC II-peptide complexes from antigens 
uptaken by the BCR169. In natural killer cells, knock-down of Myh9 impairs cytotoxicity 
through defective degranulation170. Another study has revealed that Myh9 binds natural killer 
cell granules via its tail domain and therefore enables the integration into the F-actin network 
as well as the transport to the immunological synapse to ensure exocytosis153,171.  
During the process of differentiation, Myh9 is highly upregulated in PMN resulting in the 
highest expression of Myh9 amongst the immune cells and suggesting a particular functional 
importance for this molecule in this cell type, especially, as Myh9 has to execute all functions 
that are elsewhere divided between two or three isoforms144,172. Previous studies analysing the 
role of Myh9 for PMN migration have been restricted to the use of the pharmacological 
inhibitors 2,3-butanedione monoxime (BDM) and blebbistatin. BDM operates as ATPase and 
therefore affects the activity of myosins and many non-myosin proteins. Blebbistatin blocks 
NMII activity by binding in a cleft in the motor domain. At this position it blocks the 
conformational change of the motor domain which is necessary to pull F-actin bundles 
together.173-176 Treatment of human PMN-like differentiated HL-60 cells with blebbistatin 
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suggests a role of NMIIA in the maintenance of membrane tension during establishment of 
the leading-edge protrusion and in the prevention of secondary pseudopods in 2D 
environments177. Treatment of human PMN with blebbistatin compromises tail retraction 
during transmigration through a TNFα-activated endothelial monolayer146. Similarly, studies 
with murine PMN using the inhibitor BDM as well as blebbistatin have revealed a tail 
retraction defect during 2D migration under static conditions92,93,178. Furthermore, in confined 
3D environment, blebbistatin studies in murine PMN suggest that uropod contractility relies 
on NMIIA to squeeze the nucleus through sites of constrictions87.  
These studies point to an important role of Myh9 for PMN migration. However, all these 
studies rely solely on the pharmacological inhibition of NMII. The employment of these 
inhibitors bears limitations, which obliges to take the results of the conducted studies with 
caution and reveals the necessity of genetic studies to delineate the specific function of Myh9 
in PMN.   
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1.4 Aims of the study 
NMII molecules are important molecular motors in multiple mammalian cell types. The 
distinct role of Myh9, the heavy chain of NMIIA, in the PMN recruiting cascade has been 
only unsatisfactory investigated using pharmacological inhibitors and genetic studies are 
lacking. Therefore, this study sets out to decipher the functional impact of Myh9 for PMN 
migration using genetic downregulation of Myh9 in the hematopoietic system. 
In the first part of the study, the impact of pharmacological inhibition of NMII activity on 
different steps of the PMN recruiting cascade will be analysed in vitro. In contrast to earlier 
studies, this work will focus on experiments under flow conditions to mimic the in vivo 
environment during PMN trafficking to sites of inflammation. This data will be compared to 
previous findings under static conditions to evaluate differences and similarities. 
The second part of the study will investigate the consequences of genetic downregulation of 
Myh9 on PMN trafficking. Therefore, a mouse line with a knock-down of Myh9 in the 
hematopoietic system will be generated, by employing the Vav-iCre system and Myh9fl/fl mice 
generating Vav-iCre+/Myh9wt/fl (Myh9-cHet) mice. PMN isolated from the bone marrow of 
these mice and littermate Vav-iCre-/Myh9wt/fl (control) mice, will be examined for their 
potential to migrate under flow conditions and in confined 3D collagen matrixes as well as for 
their capacity to sense and orientate towards a chemoattractant. Immunofluorescence staining 
will be employed to analyse the subcellular localisation of Myh9 and Actin in Myh9-cHet and 
control PMN. To evaluate the in vitro findings in vivo, a CXCL1-induced peritonitis model as 
well as a laser-induced ear injury model will be conducted. Furthermore, three different 
models of bone marrow chimeric mice, namely wildtype mice carrying a wildtype 
hematopoietic system, wildtype mice carrying a Myh9-cHet hematopoietic system and 
wildtype mice carrying a hematopoietic system consisting of a 50:50 mixture of wildtype and 
Myh9-cHet cells, will be generated and the CXCL1-induced peritonitis model will be 
performed to analyse whether reduced Myh9 expression in other cell types can influence the 
trafficking behaviour of PMN in that model. 
The third aim of this work is the performance of rescue experiments to verify the results with 
the Myh9-cHet mice, as specifically caused by the reduced Myh9 expression. For this 
purpose, an immortalized hematopoietic progenitor cell line that can be differentiated towards 
PMN will be used, as PMN cannot be genetically manipulated. To this end, Hoxb8-SCF 
cell-derived neutrophils (dHoxb8 cells) are to be established as a tool to study PMN 
trafficking in vitro. The optimisation of differentiation towards PMN will be based on the 
phenotypic comparison between murine bone marrow-derived PMN and dHoxb8 cells, 
  Aims of the study 
29 
 
comparing nuclear morphology and cell surface progenitor and murine PMN markers. In 
addition, the behaviour of dHoxb8 cells in functional assays will be assessed. Hoxb8-SCF cell 
lines will be generated from progenitor cells of the foetal liver of Vav-iCre-/Myh9fl/fl, 
Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl (Myh9-knock-down) embryos. A Myh9-EGFP 
expressing Myh9-knock-down Hoxb8-SCF cell line (Myh9-RES) will be generated and 
Myh9-RES dHoxb8 cells will be compared to Myh9-knock-down dHoxb8 cells in their 
efficiency to migrate under flow conditions and in 3D collagen matrixes. To draw conclusions 
on the function of Myh9 for migration, the spatial-temporal localisation of Myh9 during 
migration will be analysed using live-cell imaging of migrating Myh9-RES dHoxb8 cells. 
Altogether, this study aims to shed light on the mechanistic involvement of Myh9 in PMN 
migration in innate immunity. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents and Kits 
Name Source
2-Mercaptoethanol Sigma Aldrich 
10 % SDS-solution Applichem
30 % Bis-acrylamidsolution Applichem
Acetic acid Applichem
Agarose Genaxxon
Ammonium chloride (NH4Cl) Sigma Aldrich 
Ammoniumperoxodisulfate (APS) Applichem
Ampicillin AppliChem
Bacto tryptone Th. Geyer
BD FACS™ lysing solution BD Bioscience 
Bovine serum albumine (BSA) Sigma Aldrich 
Bromphenole blue AppliChem
β-Estradiol Sigma Aldrich 
Calcium chloride (CaCl2) AppliChem
Collagen type I, rat tail IBIDI GmbH 
Cortrimoxazol Ratiopharm
Crystal violet Sigma Aldrich 
Diisopropyl phosphofluoridate (DFP) Sigma Aldrich 
Dimethyl sulfoxide (DMSO) AppliChem
Dithiothreitol (DTT) AppliChem
DNeasy Blood & Tissue Kit QIAGEN
Dulbecco’s modified Eagle medium (DMEM) Biochrom
eBioscienceTM Intracellular Fix & Perm Set Thermo Fisher Scientific 
Essential medium (Opti-MEM) Thermo Fisher Scientific 
Ethanol absolute Th. Geyer
Ethylenediamine-tetraacetic acid (EDTA) AppliChem
FACS Lysing Solution BD Bioscience 
Foetal calf serum (FCS) Biochrom
FITC-Dextran Sigma Aldrich 
GeneRuler™ 1 kb DNA ladder Nippon
GeneRuler™ 100 bp DNA ladder Nippon
Giemsa’s azur eosin methylene blue Sigma Aldrich 
Glucose AppliChem
Glutaraldehyde solution Sigma Aldrich 
Glycine AppliChem
Hank’s balanced salt solution Biochrom
HEPES AppliChem
HISTOPAQUE® 1083 Sigma Aldrich 
Hydrochloric acid, 37% (HCl) AppliChem
In-Fusion® HD Cloning Kit  Clontech - Takara Bio Company
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Intracellular Fixation & Permeabilization Buffer Set eBioscience™ 
Isopropanol Merck KGaA 
Lipofectamin® Transfection Reagent Thermo Fisher Scientific 
Lipofectamin® 2000 Transfection Reagent Thermo Fisher Scientific 
Magnesium chloride (MgCl2) AppliChem
May-Grünwald solution AppliChem
Methanol Th. Geyer
Midori Green Nippon
Modified Eagle’s minimum Thermo Fisher Scientific 
NucleoBond Xtra Maxi Plus EF Macherey-Nagel 
NucleoSpin Gel and PCR Clean-up Macherey-Nagel 
Odyssey® Blocking Buffer (TBS) LI-COR Biosciences 
PageRuler™ prestained protein ladder Thermo Fisher Scientific 
Paraformaldehyde (PFA) 37% Sigma Aldrich 
Phorbol myristate acetate (PMA) Merck
PCRBio Rapid Extract PCR Kit Nippon
Penicillin / Streptomycin (P/S) Biochrom
Percoll Sigma Aldrich 
Phenol red Biochrom
Phosphate buffered saline (PBS) Biochrom
Pn-blebbistatin Optopharma Ltd. 
Poly-L-Lysin Merck
Ponceau solution Applichem
Potassium bicarbonate (KHCO3) Sigma Aldrich 
ProLongTM Gold antifade reagent Thermo Fisher Scientific 
Protease inhibitor Mix B Sigma Aldrich 
PureYield™ Plasmid Miniprep System Promega
Qubit™ Protein Assay Kit Thermo Fisher Scientific 
Roswell Park Memorial Institute 1640 (RPMI) medium Biochrom
SiR-actin Spirochrom
Sodium chloride (NaCl) AppliChem
Sodium dihydrogen carbonate (NaH2PO4) Sigma Aldrich 
Sodium dodecyl sulfate (SDS) AppliChem
Sodium fluoride Sigma Aldrich 
Sodium hydrogen carbonate (Na2HCO3) AppliChem
Sodium orthovanadate Sigma Aldrich 
TEMED Applichem
TritonX-100 Sigma Aldrich 
Trizma base (Tris) Applichem
Trypsin/EDTA Biochrom
Tween 20 Sigma Aldrich 
Yeast extract Applichem
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2.1.2 Buffers 
Name Ingredients
2x Lämmli-buffer 
H2Odest  
+ 125 mM Tris-HCl pH 6,8 
+ 4 % SDS 
+ 20 % Glycerol 
+ 10 % 2-Mercaptoethanol 
+ 0,002 % Bromphenol blue
Adhesion medium (ADM) 
Hank’s balanced salt solution 
+ 1.2 mM Ca2+ 
+ 1 mM Mg2+ 
+ 0.25 % BSA 
+ 0.1 % Glucose 
+ 20 mM Hepes  
pH 7.4
Cell lysis buffer 
H2Odest 
+ 25 mM Tris-HCl pH 7.4 
+ 150 mM NaCl 
+ 0.5 mM EDTA 
+ 1 % TritonX-100 
+ 1% (w/v) Sodium deoxycholate 
+ 1 mM DTT 
+ 1x Protease inhibitor (Sigma) 
+ 1 mM DFP 
+ 20 mM Sodium fluoride 
+ 2 mM Sodium orthovanadate
Immune fluorescence (IF) 
antibody staining solution 
H2Odest 
+ 1% (w/v) BSA 
+ 0.1% TritonX-100
IF Perm/Block solution 
H2Odest 
+ 5% (w/v) BSA 
+ 0.3% TritonX-100
Luria broth (LB) medium  
H2Odest 
+ 0.01% (w/v) Bacto tryptone 
+ 0.005% (w/v) Yeast extract 
+ 0.01% (w/v) NaCl 
pH 7.0
Red blood cell lysis buffer 
H2Odest 
+ 150 mM NH4Cl 
+ 10 mM KHCO3 
+ 1 mM EDTA 
pH 7.2 – 7.4
SDS PAGE running buffer 
H2Odest 
+ 200 mM Glycine 
+ 25 mM Tris 
+ 0.1% (w/v) SDS
TAE buffer 
H2Odest 
+ 40 mM Tris 
+ 20 mM Sodium acetate
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+ 1.25 mM EDTA  
pH 8.5
TBST  
H2Odest 
+ 20 mM Tris 
+ 137,2 mM NaCl 
pH 7,6 
+ 0,1 % Tween
Transfer buffer 
H2Odest 
+ 25 mM Tris 
+ 192 mM Glycine 
+ 20% Methanol
Western Blot (WB) separating 
gel  buffer 
H2Odest 
+ 1,5 M Tris  
pH 8,8
WB stacking gel buffer 
H2Odest 
+ 0,5 M Tris 
pH 6,8 
 
2.1.3 Primers and restriction enzymes 
Name 5’-3’ Sequence
Myh9 genotyping forward 
(fwd) 1 
TGTCATTAGTGTCCTGAGAGCAG 
Myh9 genotyping reverse (rev) CAGGCATGGAGTTTGTGATG
Myh9 genotyping fwd 2 CCTTACCCCAGGTTTCAGGT
Vav-iCre genotyping fwd GCCTGCCCTCCCTGTGGATGCCACCT 
Vav-iCre genotyping rev GTGGCAGAAGGGGCAGCCACACCATT 
Myh9-EGFP In-Fusion 
cloning fwd 
GAATTAGATCGAATTCATGGTGAGCAAGGGCGAG
Myh9-EGFP In-Fusion 
cloning rev  
AATTAGATCTCTCGAGCGCCTATTCAGCTGCCTT 
EcoRI New England Biolabs
XhoI New England Biolabs
 
2.1.4 Antibodies 
Target Label Company 
Clone or 
catalogue 
number
Isotype Dilution/Application 
Actin  
Santa Cruz 
Biotechnology 
I19 
Rabbit 
polyclonal
1:1000 / WB 
CD11a PE BD Bioscience 2D7 Rat IgG2a 
1:100 / Flow cytometry 
(FC) 
CD11b PE eBioscience M1/70 Rat IgG2b 1:200 / FC 
CD11c APC eBioscience N418 
Armenian 
Hamster 
IgG
1:50 / FC 
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CD18 PE, FITC BD Bioscience C71/16 Rat IgG2a 1:100 / FC 
CD34 APC eBioscience RAM34 Rat IgG2a 1:50 / FC 
CD44 Pe-Cy7 eBioscience IM7 Rat IgG2b 1:400 / FC 
CD45.1 AF488 BioLegend A20 
Mouse 
IgG2a
1:200 / FC 
CD45.2 APC/Cy7 BioLegend 104 
Mouse 
IgG2a
1:100 / FC 
c-Kit 
PerCP-
eF710 
eBioscience 2B8 Rat IgG2b 1:200 / FC 
CXCR2 AF647 BioLegend TG11 Rat IgG2a 1:50 / FC 
F4/80 APC eBioscience BM8 Rat IgG2a 1:50 / FC 
Flt3 PE eBioscience A2F10 Rat IgG2a 1:20 / FC 
GAPDH  
Merck 
Millipore 
6C5 Mouse IgG₁ 1:5000 / WB 
GFP  
Santa Cruz 
Biotechnology
FL 
Rabbit 
polyclonal
1:1000 / WB 
Gr-1 FITC BD Bioscience RB6-8C5 Rat IgG2b 1:50 / FC 
Ly6-G 
PerCP-
eF710 
eBioscience 1A8-Ly6g Rat IgG2a 1:200 / FC 
Ly6-G PE eBioscience 1A8-Ly6g, Rat IgG2a 
30µg/mouse / laser-
induced injury of the 
ear 
Mouse 
IgG  
IRDye® 
680RD 
LI-COR 
Biosciences 
P/N 925-
68072
donkey 
polyclonal
1:10000 / WB 
Mouse 
IgM 
 AF488 
Thermo Fisher 
Scientific 
A-21042 
Goat 
polyclonal
1:500 / FC 
Myh9  BioLegend 
Covance 
MMS-
460R H11
Mouse IgM 1:50 / FC 
Myh9  
Cell Signaling 
Technology 
#3403 
Rabbit 
polyclonal
1:1000 / WB 
1:75 / IF 
Rabbit 
IgG  
IRDye® 
800CW 
LI-COR 
Biosciences 
P/N 925-
32213
donkey 
polyclonal
1:10000 / WB 
Rabbit 
IgG  
IRDye® 
680RD 
LI-COR 
Biosciences 
P/N 925-
68073
donkey 
polyclonal
1:10000 / WB 
Rabbit 
IgG 
AF546 
Thermo Fisher 
Scientific 
A-11071 
Goat 
F(ab’)2 
1:500 / IF 
Rabbit 
IgG 
AF488 
Thermo Fisher 
Scientific 
A-11070 
Goat 
F(ab’)2 
1:500 / IF 
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2.1.5 Recombinant proteins 
Name Source
Recombinant (r) murine (m) CXCL1 PeproTech 
rmICAM-1 without Fc Stemcell
rmP-selectin with His-tag Hölzel Diagnostika Handels GmbH 
rmTNFα R&D Systems
mfibrinogen Innovative Research
rmIL-3 PeproTech
rmIL-6 PeproTech
rmG-CSF PeproTech
N-formyl-Met-Ile-Val-Ile-Leu  (fMIVIL) JPT Peptide Technologies 
 
2.1.6 Plasmids 
Name Source
pCL-Eco 
Hans Häcker; St. Jude Children's Research Hospital, 
Memphis, USA 
pMSCVneo-ER-Hoxb8 
Hans Häcker; St. Jude Children's Research Hospital, 
Memphis, USA
pMSCV-Puro 
Hans Häcker; St. Jude Children's Research Hospital, 
Memphis, USA
pMyosin-IIA-GFP 
Addgene plasmid #38297; donated by M. Krummel, 
University of California San Francisco, USA 160 
pMSCV-Puro-Myosin-II-A-GFP Self-made
 
2.1.7 Cell lines 
Name Description  Source
b.End3 
Immortalised mouse brain endothelial 
cell line
ATCC® CRL-2299™ 
HEK-293T 
Immortalised human embryonal 
kidney cell line 
ATCC® CRL-11268™ 
NIH-3T3  
Immortalised murine embryonic 
fibroblast cell line 
DSMZ ACC 59 
WEHI-3B 
Murine myelomonocytic leukemia 
cell line producing mIL3
DSMZ ACC 26 
Hoxb8-SCF 
Immortalised murine progenitor cell 
line 
Self-made 
CHO-MGF 
Immortalised Chinese hamster ovary 
cell line producing stem cell factor 
(SCF)  
Hans Häcker; St. Jude Children's 
Research Hospital, Memphis, USA 
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2.1.8 Cell culture media 
Composition Applied for
RPMI 1640 
+ 10% FCS 
+ 1% P/S  
WEHI-3B, NIH-3T3, HEK-293T, CHO-
MGF  
DMEM+ GlutaMAX-I 
+ 10% FCS 
+ 1% P/S 
b.End3 
RPMI 1640 
+ 10% FCS 
+ 1% P/S 
+ 20% IL-3 containing WEHI-3B supernatant
Murine bone marrow-derived PMN 
RPMI 1640  
+ 15% FCS 
+ 1% P/S 
+ 10 ng/mL rmIL-3  
+ 20 ng/mL rmIL-6 
+ 2% SCF-containing supernatant 
Bone marrow or embryonic liver progenitor 
cells (stem cell medium)  
RPMI 1640 
+ 10% FCS 
+ 1% P/S 
+ 4% SCF containing CHO supernatant 
+ 30 µM beta 2-mercaptoethanol 
+ 10 µM β-Estradiol 
Hoxb8-SCF cells 
RPMI 1640 
+ 10% FCS 
+ 1% P/S 
+ 4% SCF containing CHO supernatant 
+ 20 ng/ml G-CSF 
Hoxb8-SCF differentiation towards PMN  
FCS 
+ 10% DMSO 
Cryo-conservation  
 
2.1.9 Software 
Name Company
Adobe Photoshop, Illustrator, Acrobat X Pro Adobe
Chemotaxis and migration tool IBIDI GmbH
EndNote X7.7 Clarivate Analytics
FACS Diva BD Biosciences
FlowJo V10 Treestar
Fiji/ImageJ  NIH
Image Studio Lite V5.2 LI-COR Biosciences 
LAS X Leica Application Suite Leica
Microsoft Office Microsoft Corporation 
SigmaPlot 12.5 Systat Software GmbH 
Serial Cloner 2.6 Serial Basics
Slidebook 6.0.8 3i Intelligent Imaging Innovations GmbH
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2.2 Methods 
2.2.1 Mice and Genotyping  
In this study, two different strains of mice were crossed to obtain a deletion of Myh9 in the 
hematopoietic system. Myh9fl/fl mice (stock no: 36749-JAX167, The Jackson Laboratory) were 
bred with Vav-iCre+ mice (stock no: 018968179, The Jackson Laboratory) to receive 
Vav-iCre+/Myh9wt/fl mice. Subsequently, Vav-iCre+/Myh9wt/fl mice were backcrossed to 
Myh9fl/fl mice to generate Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl target animals as well as 
Vav-iCre-/Myh9wt/fl and Vav-iCre-/Myh9fl/fl littermate controls. These mice were bred and 
housed under specific pathogen-free conditions and both male and female mice from the age 
of 8 weeks were used in the experiments. Animal experiments were conducted in accordance 
with German federal animal protection laws and were approved by the Bavarian Government 
(Regierung von Oberbayern, Munich, Germany)180. 
To analyse the genotype of the mice, DNA was extracted from ear biopsies using the PCRBio 
Rapid Extract PCR Kit and genotyping PCRs were performed according to manufacturer’s 
protocol. Here, the primers Myh9 genotyping fwd 1 and Myh9 genotyping rev were applied to 
distinguish, on the basis of different sizes of the PCR products, between wildtype (Myh9wt) 
and floxed exon1 of Myh9 (Myh9fl) alleles. To identify Vav-iCre+ mice, the presence, or for 
Vav-iCre- mice, the absence, of a PCR product with the genotyping primers Vav-iCre 
genotyping fwd and Vav-iCre genotyping rev was documented. To further characterise the 
Myh9 gene locus in Hoxb8-SCF cells, an additional genotyping PCR was performed. A new 
Myh9 forward primer - Myh9 genotyping fwd 2 - was employed, along with the Myh9 
genotyping rev primer. This strategy allowed the discrimination between Myh9wt and Myh9fl 
alleles as well as Myh9 with a deleted exon 1 (Myh9del). The positions of the Myh9 primers 
around exon 1 of Myh9 are illustrated in Fig. 4. The PCR protocols started with an initial 
denaturation step at 95°C for 3 min, followed by a 33 times repeated loop including 
denaturation for 15 s at 95°C, annealing for 15 s at 60°C for Myh9 primers and 65°C for 
Vav-iCre primers, and elongation at 72°C for 30 s for Myh9 genotyping fwd 1 and Myh9 
genotyping rev primers, 2 min for Myh9 genotyping fwd 2 and Myh9 genotyping rev primers, 
and 1 min for Vav-iCre primers. A final elongation step at 72°C for 2 min ended the PCR 
protocol. Using gel electrophoresis in a 1.5% agarose gel in TAE buffer, the DNA fragments 
were separated according to their size and visualized with the help of Midori green and UV 
light. The usage of a DNA ladder allowed the determination of the actual band sizes, with 
800 bp for Vav-iCre+ and no band for Vav-iCre-, 350 bp for Myh9wt or 480 bp for Myh9fl in 
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the original genotyping PCR and 1800 bp for Myh9wt, 2000 bp for Myh9fl or 240 bp Myh9del in 
the additional genotyping PCR. 
 
 
Figure 4. Schematic representation of Myh9fl allele and genotyping PCR products. 
Purple box indicates the exon 1 of Myh9. Red arrows display the location of flox sites and 
orange boxes represent the 2 different fwd primers Myh9 genotyping forward (fwd) 1 and 2, 
and the location of the Myh9 genotyping reverse (rev) primer. These primers were used to 
distinguish between Myh9fl, Myh9wt, and Myh9del DNA according to specific lengths of the 
PCR products. Schematic representation of (A) the Myh9fl allele, (B) the PCR products for 
the original genotyping PCR using the primers fwd1 and rev and (C) the PCR products for the 
additional genotyping PCR using the primers fwd2 and rev. 
 
2.2.2 Cell culture 
All cell lines were cultured in their appropriate media at 37°C, 5% CO2 and 95% air humidity 
to ensure optimal growth conditions. With the exception of the Hoxb8-SCF cells, all other cell 
lines had an adherent phenotype and were sub-cultured once they reached 90% confluence. 
To detach the cells, Trypsin/EDTA was applied and a portion of the cells was transferred to a 
new culture dish with fresh culture medium. To produce SCF containing supernatant from 
CHO-MGF cells or IL-3 containing supernatant from WEHI-3B cells, these cells were 
allowed to grow in 100% confluence for 2 days (d) before the medium was collected. 
Hoxb8-SCF cells were grown in suspension and were sub-cultured by transferring a portion of 
the cell suspension into a cell culture flask with fresh culture medium. For long term storage, 
adherent cells after detachment or cells in suspension were pelleted at 300 x g, resuspended in 
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freezing medium at 2 x 106 cells per mL and aliquoted into cryotubes. These were cooled 
down to -80°C in a NALGENE™ Cryo 1°C freezing container (Thermo Fisher Scientific) 
before the transfer to liquid nitrogen. To re-cultivate cells, a 37°C water-bath was employed 
to quickly thaw the cells before uptake in fresh culture medium. To wash out residual DMSO, 
the cells were centrifuged at 300 x g and transferred into a new cell culture flask with fresh 
culture medium. Determination of exact cell numbers is crucial for all in vitro assays. Here, 
trypan blue staining was used to discriminate between live and dead cells and cell numbers 
were calculated using a Neubauer counting chamber (Th. Geyer).  
 
2.2.3 Isolation of murine bone marrow PMN 
PMN were isolated by flushing out bone marrow cells from tibia, femur and humerus of mice 
with PBS and loading of the obtained cells onto a discontinuous Percoll density gradient 
(52% / 64% / 72%), followed by centrifugation at 1000 x g for 30 min without break. Due to 
their specific density, PMN could be collected from the interphase between 64% and 72% 
Percoll and were cultivated for 24 hours (h) in RPMI 1640 supplemented with 20% WEHI-
3B-conditioned medium180,181. 
 
2.2.4 Pharmacological inhibition of Myh9 
In this study, para-nitro blebbistatin (pn-blebbistatin) was used to inhibit NMII activity 
pharmacologically. Prior to the experiment, murine bone marrow-derived PMN were 
incubated with 1 µM, 5 µM, 15 µM, 25 µM or 50 µM pn-blebbistatin at 37°C for 30 min. The 
indicated concentrations of pn-blebbistatin were also applied during the entire duration of the 
assays to prevent a wash-out of the inhibitor180. 
 
2.2.5 Generation and differentiation of Hoxb8-SCF cells  
In the first step of Hoxb8-SCF cell generation, a retrovirus encoding for the fusion protein of 
an estrogen responsive element (ER) and Hoxb8 was produced. Here, HEK-293T cells were 
grown to 90% confluency in a 10 cm2 dish and transfected with 8 µg of the retroviral 
backbone pMSCVneo-ER-Hoxb8 as well as the ecotropic packaging vector pCL-Eco using 
Lipofectamin® 2000. The retrovirus containing supernatant was harvested 48 h post 
transfection, aliquoted, and stored at -80°C for later usage. To verify the amount of infectious 
virus particles in the supernatant, the colony forming units (cfu)/mL of the virus were 
assessed by titration using NIH3T3 cells. In the second step of the Hoxb8-SCF cell 
generation, bone marrow progenitor cells or foetal liver progenitor cells were transduced with 
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the ER-Hoxb8 encoding retrovirus. Bone marrow cells from the tibia of 8 - 10 week old mice 
or E13 foetal liver cells were harvested using PBS + 1% FCS. Progenitor cells were enriched 
by centrifugation for 30 min at 400 x g without break using HISTOPAQUE® 1083. At the 
interphase between PBS and the HISTOPAQUE® 1083, mononuclear cells were harvested, 
and progenitor cells were stimulated to proliferate by culture in 10 mL stem cell medium for 
3 d at a starting concentration of 5 x 105 cells/mL. These stimulated progenitor cells were 
transduced with the ER-Hoxb8 encoding retrovirus at a multiplicity of infection of 10 by 
spinoculation for 80 min at 1500 x g with the help of Lipofectamin® in a final dilution of 
1:1000 in Hoxb8-SCF medium. The Hoxb8-SCF cell line was established after 4 weeks by 
continuous sub-culture in Hoxb8-SCF medium. 
To accomplish differentiation of Hoxb8-SCF cells into PMN, 2.5 x 105 cells were washed in 
PBS and were allowed to grow in 10 mL differentiation medium in a 10 cm2 culture dish for 
4 d180. 
 
2.2.6 Generation of Myh9-EGFP expressing Hoxb8-SCF cells 
To generate Myh9-EGFP expressing Hoxb8-SCF cells, cells were transduced with a 
retrovirus encoding for Myh9-EGFP and a puromycin resistance: First, the coding region of 
Myosin-IIA-GFP was cloned into the retroviral backbone pMSCV-Puro using the In-Fusion® 
HD Cloning Kit. The underlying cloning method is ligation independent and based on 
annealing of 15 bp long complementary overlaps of a cloning insert and the linearized cloning 
vector. Here, the homologous overlaps were generated by PCR amplification of the 
Myh9-EGFP locus using the specifically designed primers Myh9-EGFP In-Fusion cloning 
fwd and rev. The In-Fusion® enzyme mix generated 15 bp single stranded 5’ overhangs at the 
termini of the cloning insert and the linearized vector. These overhangs annealed at the sites 
of complementarity, and the recombinant circular construct was rescued in Stellar competent 
E. coli cells182. In a second step, retrovirus encoding for Myh9-EGFP and a puromycin 
resistance was produced in HEK-293T cell using the generated pMSCV-Puro-
Myosin-II-A-GFP and the ecotropic packaging vector pCL-Eco. Virus-containing supernatant 
was harvested 48 h post transfection, and Vav-iCre+/Myh9fl/fl foetal liver Hoxb8-SCF cells 
were transduced by spinoculation. After 72 h of transduction 10 µg/mL puromycin was added 
to the cell culture medium to select for puromycin resistant cells. The puromycin resistant 
cells where further analysed for their expression of EGFP and EGFPhigh Hoxb8-SCF cells 
were sorted using a MoFlo Astrios cell sorter (Beckman Coulter). In the last step of the 
generation of Myh9-EGFP expressing Hoxb8-SCF cells, the expression of the Myh9-EGFP 
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fusion protein in Vav-iCre+/Myh9fl/fl foetal liver Hoxb8-SCF cells was confirmed using 
western blotting and flow cytometry180. 
 
2.2.7 Western blotting  
To analyse protein expression using western blot, cells were lysed at a concentration of 
1 x 107 per 300 µL in cell lysis buffer for 30 min at 4°C. Subsequent centrifugation at 
1500 x g for 5 min ensured that the cell debris was separated from the proteins in suspension. 
The protein concentration was determined using the Qubit™ Protein Assay Kit. To denature 
and reduce the proteins, the samples were incubated for 7 min at 97°C in 2x Lämmli-buffer. 
For separation of proteins on the basis of their molecular weight and charge, total protein 
lysates were run on SDS-PAGEs. In this study, polyacrylamide gels with 8% separating and 
4% stacking gels were used, and proteins were separated by electrophoresis using 80 Volt and 
120 Volt. Transfer of proteins onto nitrocellulose membranes was carried out by semi-dry 
blotting at 0.08 Ampere for 2 h. After blocking of the membrane with Odyssey® blocking 
buffer for 1 h, the membranes were incubated overnight (o.n.) at 4°C with a specific primary 
antibody in a 1:1 TBST/Odyssey® blocking buffer solution. Membranes were incubated for 
1 h with near-infrared labelled secondary antibodies to enable detection at the Odyssey® CLx 
Imaging system180. 
 
2.2.8 Flow cytometry 
Upregulation of integrins after stimulation was evaluated in Hoxb8-SCF cells using flow 
cytometry and specific fluorescence-labelled antibodies. Cells (2.5 x 105 per sample) were 
incubated with 100 ng/mL rmTNFα, 100 ng/mL rmCXCL1, 100 nM PMA or 100 nM 
N-formyl-Met-Ile-Val-Ile-Leu (fMIVIL) 183 or PBS for control for 20 min at 37°C before 
application of the indicated antibodies or corresponding isotype controls for 30 min on ice in 
PBS supplemented with 1% FCS. Labelled cells were kept on ice and acquired immediately 
after washing on a FACSCanto II or a LSRFortessa flow cytometer (BD Bioscience). For 
analysis of extracellular markers on murine blood PMN, the antibody solution was directly 
added to 50 µL whole blood taken from the vena maxillaris and vena temporalis superficiali 
and incubated for 30 min at 4°C. Red blood cells were removed by adding 1 mL FACS 
Lysing Solution and incubation for 10 min on ice. For detection of intracellular Myh9, the 
eBioscienceTM Intracellular Fixation & Permeabilization Buffer Set was applied. Hoxb8-SCF 
cells (5 x 105) were fixed in 100 µL fixing solution at room temperature (RT) for 20 min. 
After washing with PBS, the cells were incubated with 1 mL permeabilization buffer for 
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10 min at RT, followed by 30 min incubation of the Myh9 specific primary antibody in 50 µL 
permeabilization buffer on ice. The adequate AF488-labelled anti-mouse IgM secondary 
antibody was subsequently incubated with the cells in 50 µL perm buffer on ice, before 
acquisition of cells on the flow cytometer. Fluorescence intensities were measured, and mean 
fluorescence intensities and histograms were determined using FlowJo V10 software, after 
exclusion of dead cells before gating on the target population180. 
 
2.2.9 Microscopy 
2.2.9.1  May-Grünwald-Giemsa staining  
For May-Grünwald-Giemsa staining, cytospins of Hoxb8-SCF cells and murine bone marrow-
derived PMN (1 x 105 cells) were stained with the May-Grünwald solution for 3 min and 
subsequently stained with a 12% Giemsa solution for 20 min. Microscopy was conducted 
after drying of the samples o.n. using a 63x/1.4NA oil immersion objective (Leica)180. 
 
2.2.9.2  Confocal microscopy  
Subcellular distribution of Myh9 and F-actin in transfected HEK-293T cells was analysed 
using confocal microscopy. HEK-293T cells were grown to 90% confluence in vitro on a 
gelatine-treated cover slip before fixation with 4% PFA in PBS for 10 min on RT, treatment 
with IF Perm/Block solution for 1 h at RT and incubation with the primary anti-Myh9 
antibody and 100 nM SiR-actin (Spirochrome) in IF antibody staining solution o.n. at 4°C. 
After washing with PBS, the secondary anti-rabbit AF546-labelled antibody was applied to 
the coverslips for 1 h before mounting of the samples using ProLongTM Gold antifade 
reagent180. Images were taken using a Leica SP8X WLL confocal microscope equipped with a 
63x/1.40 oil immersion objective (Leica) and analysed offline using LAS X software and 
Fiji/ImageJ. 
 
2.2.9.3  Stimulated emission depletion (STED) nanoscopy  
For the identification of the subcellular localisation of Myh9 and F-actin in PMN isolated 
from Vav-iCre+/Myh9wt/fl (Myh9-cHet) and Vav-iCre-/Myh9wt/fl (control) mice, STED 
nanoscopy was used. Here, PMN were stimulated and allowed to adhere by exposure to a 
glass surface coated with 3 µg/mL rmICAM-1 and 5 µg/mL rmCXCL1 for 10 min in an 
IBIDI 12 well chamber. Fixation and staining of PMN was conducted as described for 
HEK-293T cells. Here, the anti-rabbit AF488-labelled secondary antibody was used to 
visualise Myh9. Samples were mounted using ProLongTM Gold antifade reagent and images 
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were taken using sequential recording at a Leica TCS SP8X WLL STED microscope 
equipped with a 100x/1.4NA oil immersion objective and depletion in xy direction at 592 nm 
and 775 nm180. Images were analysed offline using LAS X software and Fiji/ImageJ. 
Quantification of the subcellular localisation of Myh9 and F-actin in Myh9-cHet and control 
PMN was performed by splitting the area of the cells equally into two parts, the front and the 
back of the cell. Myh9 and F-actin distribution to the front or the back of the cell was 
determined by taking the sum of intensity values of the whole cell area and calculating the 
ratio between this value and the sum of intensity values of the front or the back of the cell. To 
determine the spatial correlation between F-actin and Myh9, a randomization approach using 
the nearest-neighbour analysis was performed with the MosacIA Fiji plugin to calculate the 
interaction potentials184,185. Potential used was Plummer (10 iterations). Grid spacing was 0.5 
pixels. Kernel wt(q) was 0.001. Kernel wt(p) was provided by the plugin using Silverman’s 
rule. Interaction strength > 0 indicated that the spatial distribution of F-actin was dependent 
on the spatial distribution of Myh9. The results were tested for significance against 1,000 
Monte Carlo samples of point distributions corresponding to the null hypothesis of ‘no 
interaction’. Quantification of the interaction strength was performed using only results, 
which were considered statistically significant (p < 0.05)180. 
 
2.2.9.4  Live cell imaging using spinning disk confocal microscopy 
Subcellular localisation of Myh9-EGFP was analysed in real-time in Myh9-EGFP expressing 
Myh9-RES Hoxb8-SCF cell derived neutrophils (dHoxb8 cells), during chemotactic migration 
within a 1.5 mg/mL collagen network towards a rmCXCL1 gradient, as described in the 
section 3D chemotaxis. For this purpose, an upright spinning disk confocal microscope 
(Examiner, Zeiss) equipped with a confocal scanner unit CSU-X1 (Yokogawa Electric 
Corporation), an Evolve 512 EMCCD camera (Photometrics) and a 20x/0.75NA water 
immersion objective (Plan Apochromat, Zeiss) was employed. Images were acquired using a 
laser with an excitation wavelength of 488 nm. Data was analysed offline using Slidebook 
6.0.8 Software and Fiji/ImageJ180. The area of the cell was equally split into two parts, the 
front and the back of the cell. Myh9 distribution to the front or the back of the cell was 
determined as described in the section above.  
 
2.2.10 Adhesion under static conditions 
Hoxb8-SCF cells were plated in triplicates in ADM at 1 x 105 cells per well in a 96-well 
microtiter plate. Wells were either coated with rmICAM-1 (3 µg/mL) or mfibrinogen 
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(50 µg/mL) o.n. at 4 °C. Cells were allowed to adhere for 5 min and stimulated for 5 min with 
100 ng/mL rmTNFα, 100 ng/mL rmCXCL1, 100 nM PMA and 100 nM fMIVIL (final 
concentrations) or left untreated for negative control. Non-adherent cells were washed away, 
and adherent cells were fixed with 1% glutaraldehyde in PBS. After drying, cells were stained 
with 0.1% crystal violet in PBS and lysed using 10% acetic acid in H2O103. Absorption was 
measured at 590 nm with a microplate reader (TECAN). All samples were normalized to the 
untreated control cells (100% = 1) and fold change of adhesion was displayed180. 
 
2.2.11 Adhesion under flow conditions 
To study induction of adhesion under flow conditions of murine bone marrow-derived PMN 
and dHoxb8 cells IBIDI µ-Slide VI 0.1 flow chambers were coated o.n. at 4°C with 10 µg/mL 
rmP-selectin for PMN and 5 µg/mL rmP-selectin for dHoxb8 cells, 3 µg/mL rmICAM-1, and 
5 µg/mL rmCXCL1. Cells (7.5 x 105/mL) in ADM were perfused into the channels for 9 min 
at a constant shear stress of 1 dyne/cm2. An Axiovert 200M microscope equipped with a Plan-
Apochromat 20×/0.75NA objective, AxioCam HR digital camera, and a temperature-
controlled environmental chamber (Zeiss) were used, and time-lapse videos were recorded 
from 18 different points of view. The number of rolling and adherent cells after 1, 3, 5, 7 and 
9 min was determined offline using Fiji/ImageJ as described previously180,186,187. 
 
2.2.12 Spreading and polarisation  
Spreading and polarisation of murine bone marrow-derived PMN were studied in IBIDI 
µ-Slide VI 0.1 flow chambers coated with rmICAM-1 (3 µg/mL) and rmCXCL1 (5 µg/mL) as 
described previously180,186,187. The PMN (4 x 105/sample) in ADM were perfused into the 
channels and allowed to adhere for 10 min under static conditions. Pictures were taken with 
the above described microscope set-up and analysed offline using Fiji/ImageJ by measuring 
the cell area and circularity.  
 
2.2.13 2D mechanotaxis 
Mechanotactic crawling under shear stress of murine bone marrow-derived PMN and dHoxb8 
cells was studied in IBIDI µ-Slide VI 0.1 flow chambers coated with rmICAM-1 (3 µg/mL) 
and rmCXCL1 (5 µg/mL). The chambers were perfused with PMN or dHoxb8 cells in ADM 
(4 x 105/sample) and allowed to adhere for 10 min (PMN) or 5 min (dHoxb8 cells). Shear 
stress of 1 dyne/cm2 was applied for 10 min and time-lapse videos with a time interval of 5 s 
were recorded of one field of view with the microscope set-up described in the section 
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adhesion under flow conditions187. Migration tracks were analysed offline with the ImageJ 
software and its implemented manual tracking plugin (Fabrice Cordeliès, Institute Curie, 
France)186. Single cell migration tracks rose plots and migration parameter were obtained 
using the IBIDI chemotaxis and migration tool180. 
 
2.2.14 Adhesion strengthening  
Adhesion strengthening of murine bone marrow-derived PMN was analysed using increasing 
shear stress rates in IBIDI µ-Slide VI 0.1 flow chambers coated with rmICAM-1 (3 µg/mL) 
and rmCXCL1 (5 µg/mL) as described previously186,188. Before onset of shear stress, PMN 
(4 x 105/sample) in ADM were allowed to adhere for 10 min. Shear stress was increased every 
90 s, starting from 0.5 dyne/cm2 up to 8.0 dyne/cm2. The cells that remained adherent during 
the observation period were counted and relative adhesion was quantified as percent of 
adherent cells prior to the onset of shear stress (100%)180. 
 
2.2.15 2D chemotaxis 
Chemotactic behaviour of dHoxb8 cells was investigated in a Zigmond chamber as described 
previously104,189. Glass coverslips were coated with rmICAM-1 (12.5 µg/mL) o.n. at 4 °C, 
blocked with 10 % casein at RT for 2 h and washed with PBS. Cells (4 x 105 per sample) in 
50 µL ADM were applied to the coverslip and allowed to adhere for 10 min at 37°C. 
Coverslips were placed and fixed onto the Zigmond slide. To generate a chemotactic gradient, 
ADM supplemented with 100 ng/mL mCXCL1 was applied to one side of the Zigmond 
chamber. After stabilisation of the gradient for 10 min, time-lapse videos with a time interval 
of 5 s were recorded for 10 min using the above described microscope set-up187. Single cell 
migration tracks rose plots, and the associated cell migration parameters were determined 
offline using Fiji/ImageJ and the IBIDI chemotaxis and migration tool180. 
 
2.2.16 Transwell migration assay 
Analysis of transmigration in vitro was performed using transwell polycarbonate 
filters (Corning) with a pore size of 3 µm or 8 µm, as described previously187,190. Triplicates 
of murine bone marrow-derived PMN (2.5 x 105/sample for 3 µm pore size and 5 x 
105/sample for 8 µm pore size) were seeded in 100 µL ADM in the upper compartment of the 
chamber. The lower compartment of the system contained ADM and rmCXCL1 (100 ng/mL) 
or ADM alone for control. In the first set of experiments, rmICAM-1 (3 µg/mL) coated filters, 
with a pore size of 3 µm, were used and PMN were allowed to migrate for 70 min. Here, 
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transmigrated PMN were quantified on a FACSCanto II or LSRFortessa (BD Bioscience) on 
the basis of a standard curve consisting of a dilution of PMN ranging from 2.5 x 105 cells 
(100%) to 2.5 x 103 cells (1%). The samples where further normalized to the transmigrated 
control cells in the presence of rmCXCL1 (100%). In a second set of experiments, 
brain-derived b.End3 endothelial cells were seeded in the upper compartment of chambers 
with filters displaying 8 µm pore size. After 2 d of seeding, the b.End.3 endothelial cells had 
formed a monolayer and were equilibrated for 30 min before PMN were added and allowed to 
transmigrate for 45 min at 37 °C. Here, the transmigrated PMN were collected and counted 
using a Neubauer counting chamber and trypan blue staining. The samples where normalized 
to the transmigrated control cells in the presence of rmCXCL1 (100%)180.  
 
2.2.17 3D chemotaxis 
The analysis of migration in collagen gels was performed in IBIDI µ-Slides Chemotaxis 3D 
chambers as previously described187,190. For a 1.5 mg/mL collagen gel, a gel-cell mixture with 
murine bone marrow-derived PMN or dHoxb8 cells (3 x 105) in 5 µL ADM was prepared by 
mixing cells with 2 µL 10 x ADM, 8.5 µL H2O, 0.4 µL NaHCO3, and 9 µL (5 mg/mL) type I 
rat tail collagen. The PMN/collagen solution was applied to the middle channel of the 3D 
chamber and left at 37°C for 5 min for gelation. After application of 100 ng/mL rmCXCL1 in 
ADM to one reservoir of the chamber and incubation for 20 min at 37°C, time-lapse videos 
were recorded for the length of 10 min with a frame rate of 14 s using a Plan-Apochromat 
10×/0.3NA objective and the above described microscope set-up180. Migration was analysed 
offline using Fiji/ImageJ. Cell migration tracks and rose plots were generated using the IBIDI 
chemotaxis and migration tool. 
 
2.2.18 Laser-induced injury of the ear 
Extravasation and interstitial migration of PMN during sterile inflammation was investigated 
by two-photon microscopy using a laser-induced injury model of the ear dermis of mice, as 
described previously180,191. After intraperitoneal application of anaesthesia consisting of 
Medetomidine (0.5 µg/g body weight), Midazolam 5 µg/g and Fentanyl 0.05 µg/g in 0.5 mL 
NaCl, the ears of Vav-iCre+/Myh9wt/fl (Myh9-cHet) mice and Vav-iCre-/Myh9wt/fl (control) 
mice were fixed on a custom build stage. A tail vein catheter was used to apply PE-labelled 
anti-Ly6G (30 µg, 1A8-Ly6g, eBioscience) and FITC-dextran (20 µg, 2MD, Thermo Fisher 
Scientific). Focusing the laser beam on the ear in a field of 40 µm x 40 µm until 
autofluorescence appeared led to a single necrotic lesion 192,193. Images were acquired using a 
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TrimScope II (LaVision Biotech) connected to an upright microscope with a 20x/0.95W water 
immersion objective (Olympus), excitation at 800 nm, the emission filters 525/50 and 605/70 
and second harmonics. The size of the field of view was 554 µm x 554 µm and a frame rate of 
30 s and a z-step size of 3 µm in a total range of 30 µm (20-50 µm below the epidermis) were 
chosen180. Quantification of interstitial migration velocity and Euclidean distance during the 
observation time was achieved offline by manual tracking using Fiji/ImageJ and the IBIDI 
chemotaxis and migration tool. Extravasation of PMN was evaluated over time, starting 
immediately after injury, up to 40 min. Extravascular PE intensities within a circular area of 
interest, defined by the border of the laser injury to the border of the nearest vessel, were 
measured. Quantification was performed by calculating the fold change of the sum of 
intensity values relative to the background intensity immediately after injury180. Leukocyte 
counts were determined from whole blood of the vena maxillaris and vena temporalis 
superficialis using an IDEXX ProCyte DxTM hematology analyser (IDEXX Laboratories). 
 
2.2.19 CXCL1-induced peritonitis model 
To induce peritonitis and the extravasation of PMN into the peritoneal cavity, Myh9-cHet and 
control mice or bone marrow chimeras (as described below) were injected intraperitoneally 
with 300 ng rmCXCL1 or 0.9% NaCl for negative control. After 4 h, mice were sacrificed, 
and the peritoneal cavity was flushed with 5 mL ice cold 0.9% NaCl, as described 
previously180,187,190. The number of extravasated PMN in the lavage was detected using an 
IDEXX ProCyte DxTM hematology analyser (IDEXX Laboratories). 
 
2.2.20 Bone marrow chimeras 
The congenic marker system CD45.1/2 was used for the generation of the bone marrow 
chimeras to enable discrimination of control and Myh9-cHet derived leukocytes194,195. 
CD45.1 wildtype recipient mice were irradiated twice in an interval of 4 h with 6 Gy for 
3 min. Bone marrow cells from CD45.1 wildtype and CD45.2 Myh9-cHet mice were 
harvested and a total of 10 × 106 cells per mouse were injected via tail vein into the lethally 
irradiated recipients. To prevent infections, Cortrimoxazol was given 2 d before irradiation 
until 4 weeks after transplantation. Three different chimeric models were generated 
(donor → recipient): CD45.1 wildtype → CD45.1 wildtype (WT→WT); 
CD45.2 Myh9-cHet → CD45.1 wildtype (HET→WT) and CD45.1 wildtype / CD45.2 
Myh9-cHet (1:1 ratio) → CD45.1 wildtype (MIX→WT)180. 
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2.2.21 Statistics 
Data shown represent means ± SEM and are representative or compiled from at least 
3 independent experiments as indicated. Statistical significance was performed using Sigma 
Plot 12.5. For pairwise comparison the Student t-test, for multiple comparisons, one way 
ANOVA with the Holm Sidak method or the Dunnett’s method, was applied. 
A p-value < 0.05 was considered significant180. 
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3 Results  
Major parts of the following data is published in “A fundamental role of Myh9 for neutrophil 
migration in innate immunity” by Zehrer et al. in the Journal of Immunology180. 
 
3.1 Effect of pharmacological inhibition of class II non-muscle myosin on 
PMN trafficking  
To study the effect of pharmacological inhibition of class II non-muscle myosin (NMII) 
activity on distinct steps in the recruiting cascade of PMN para-nitro blebbistatin 
(pn-blebbistatin), an inhibitor of NMII activity, was used. First, the ability of PMN to roll and 
adhere on a 2D surface was analysed under shear stress of 1 dyne/cm2 (Fig. 5A). This shear 
rate mimics the situation in vivo representing the physiological flow in postcapillary venules. 
Over the time course of 9 min, the number of rolling and adherent cells on rmICAM-1, 
rmP-selectin and rmCXCL1 was determined and was found to be similar between 
pn-blebbistatin- and DMSO-treated control PMN: After 9 min, 129 ± 26 rolling and 495 ± 35 
adherent PMN for DMSO- and 119 ± 26 rolling and 413 ± 29 adherent PMN for 
pn-blebbistatin-treated PMN were identified, indicating that NMIIA activity is dispensable for 
the process of induction of adhesion under flow conditions.  
 
 
Figure 5. Pn-blebbistatin treatment of murine bone marrow-derived PMN does not 
affect induction of adhesion but the shape of adherent cells. (A) Numbers of rolling and 
adherent cells of DMSO- or pn-blebbistatin-treated PMN under 1 dyne/cm2 of flow on 
immobilised rmP-selectin, rmICAM-1 and rmCXCL1 at indicated time points. (B) 
Representative images of adherent PMN. Cell shape descriptors determined after 10 min of 
exposure to immobilised rmICAM-1 and rmCXCL1. Cell area and circularity was calculated 
from 223 DMSO-treated PMN and 275 pn-blebbistatin-treated PMN from 4 independent 
experiments. Scale bar, 10 µm. Mean ± SEM n = 5. n.s., not significant, DMSO- versus pn-
blebbistatin-treated adherent PMN (adapted from Zehrer et al., 2018180). 
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During the spreading of PMN and the establishment of polarity a striking difference in 
morphology was observed between the two treatments. The pn-blebbistatin-treated PMN 
displayed for PMN atypical multiple protrusions. Quantitative analysis revealed that DMSO-
treated PMN had a cell area of 103 ± 3.6 µm2 compared to a significantly increased cell area 
of 123 ± 3.7 µm2 for pn-blebbistatin-treated PMN. Additionally, a significant decrease in 
circularity from 0.73 ± 0.02 µm in control PMN to 0.63 73 ± 0.01 µm after pn-blebbistatin 
treatment was observed (Fig. 5B). 
 
Subsequent to induction of adhesion and spreading, the ability to migrate under flow 
conditions is of major importance for PMN as it enables them to reach suitable extravasation 
sites from the vessel into the inflamed tissue. It was previously reported that the concentration 
of blebbistatin influences the migration speed of different cell types such as endothelial cells 
or monocytes in a dose-dependent manner196. In this study, the influence of increasing 
concentrations of pn-blebbistatin on the migration behaviour of PMN was analysed. 
Pn-blebbistatin was applied to PMN in concentrations from 0 - 50 µM and the effect on 
migration velocity was monitored during migration on immobilised rmICAM-1 and 
rmCXCL1 under flow conditions (Fig. 6A). The results revealed a concentration dependence 
of migration velocity in pn-blebbistatin-treated PMN. Higher pn-blebbistatin concentrations 
led to lower values in migration velocity with the slowest migrating PMN at 50 µM 
pn-blebbistatin with 4.3 ± 0.17 µm/min, compared to the control PMN with 9.4 ± 0.68 
µm/min migration velocity (Fig. 6A). Further analysis was carried out for PMN treated with 
50 µM pn-blebbistatin, to evaluate in detail the migration behaviour of pn-bebbistatin- versus 
DMSO-treated PMN under flow conditions (Fig. 6 B-D). Time-lapse images of recorded 
videos revealed an elongated uropod, which the cells could hardly retract, in pn-blebbistatin-
treated PMN (Fig. 6B). Interestingly, this phenotype did not occur when PMN were treated 
with 1 µM pn-blebbistatin, occurred in around half of the imaged PMN when treated with 
5 µM pn-blebbistatin, and higher concentrations caused this phenotype in all PMN (data not 
shown). Comparison of single cell migration tracks of PMN treated with pn-blebbistatin 
(50 µM) or DMSO (Fig. 6C) and quantitative evaluation of the accumulated distance and the 
Euclidean distance further elucidated the diminished migratory capacity of the pn-blebbitatin-
treated PMN (Fig. 6D). Specifically, the accumulated distance was significantly reduced from 
94.6 ± 6.8 µm in DMSO-treated PMN to 43.4 ± 1.7 µm in pn-blebbitatin-treated PMN. 
Euclidean distance was significantly reduced from 51.7 ± 4.0 µm in DMSO-treated PMN to 
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26.4 ± 0.8 µm in pn-blebbistatin-treated PMN. Thus, pn-blebbistatin-treated PMN exhibited a 
severe migration defect under flow conditions compared to control PMN. 
 
 
Figure 6. Mechanotactic migration is compromised in murine bone marrow-derived 
PMN treated with pn-blebbistatin. 1 dyne/cm2 of shear stress was applied to PMN in 
microflow chambers coated with immobilised rmICAM-1 and rmCXCL1. (A) Velocity of 
PMN treated with 0, 1, 5, 15, 25 and 50 µM pn-blebbistatin; n = 3 (B) Representative time-
lapse images of migrating DMSO- or pn-blebbistatin-treated PMN under shear stress at 
indicated time points. Scale bar, 10 µm. (C) Representative single cell migration tracks 
documented over 10 min. Arrows indicate direction of flow. (D) Accumulated and Euclidean 
distance. n = 4 (with a total of 422 DMSO-treated PMN and 563 pn-blebbistatin-treated 
PMN). Mean ± SEM, ** p < 0.01, *** p < 0.001 (adapted from Zehrer et al., 2018180). 
 
To investigate whether the inhibition of NMIIA activity could also affect the transmigration 
of PMN, pn-blebbistatin-treated or DMSO-treated control PMN were permitted to migrate 
through a membrane with 3 µm pores towards the chemoattractant rmCXCL1 in vitro (Fig. 7). 
In the case of DMSO treatment, when no stimulus was present, 23 ± 5% of control PMN 
migrated through the pores. Upon application of the chemoattractant the number of 
transmigrated PMN increased notably (100%) (Fig. 7). This was in strong contrast to the 
pn-blebbistatin-treated cells where 4.5 ± 0.7% of the PMN transmigrated with or without the 
presence of the chemoattractant in the lower compartment of the transmigration chamber. 
This experiment demonstrated that the transmigration of pn-blebbistatin-treated PMN was 
significantly decreased compared to control cells, especially in the presence of rmCXCL1. 
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Figure 7. Transmigration through 3 µm pores is diminished in pn-blebbistatin-treated 
murine bone marrow-derived PMN. Quantitative analysis of transmigrated DMSO- and pn-
blebbistatin-treated PMN towards a gradient of rmCXCL1 or without stimulus (-). 
Transmigrated PMN were normalized to DMSO-treated cells in the presence of rmCXCL1 
(100%). n = 4. Mean ± SEM. ** p < 0.01 (adapted from Zehrer et al., 2018180). 
 
 
3.2 PMN trafficking upon genetic downregulation of Myh9 in the 
hematopoietic system of mice  
The next part of the study focused on investigating the distinct role of Myh9, the heavy chain 
of the NMII complex, using a genetic mouse model. A global knock-out of Myh9 was 
reported to be lethal at embryonic day 7.5126. Therefore, a conditional knock-out (cKO) of 
Myh9 in the hematopoietic system was intended for this study. Mice expressing Cre 
recombinase under the Vav promotor (Vav-iCre+) were crossed with Myh9fl/fl mice. Offspring 
with a Vav-iCre+/Myh9wt/fl genotype was bred with Myh9fl/fl mice, to generate the 
Vav-iCre+/Myh9fl/fl cKO target animals.  
 
 
Figure 8. Diminished expression of Myh9 in PMN of Myh9-cHet mice. (A) Representative 
western blot of PMN lysates of control (ctrl) and Myh9-cHet mice (B) Quantitative analysis 
of Myh9 expression. Myh9 expression was normalized to the amount of GAPDH and ctrl 
mice (100%). Mean ± SEM, n = 5, ** p < 0.01 (adapted from Zehrer et al., 2018180).  
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As a result, 185 pups from 18 different mating pairs were analysed for their genotypes and 
Vav-iCre+/Myh9wt/fl, Vav-iCre-/Myh9wt/fl and Vav-iCre-/Myh9fl/fl mice were identified. 
However, no living offspring with a Vav-iCre+/Myh9fl/fl cKO genotype was found. 
Consequently, it was hypothesised that the cKO of Myh9 in the hematopoietic system is 
lethal. Therefore, experiments with PMN lacking Myh9 were not possible. Subsequently, the 
expression of Myh9 in PMN of Vav-iCre+/Myh9wt/fl (Myh9-cHet) mice was evaluated (Fig. 8). 
Interestingly, in Myh9-cHet PMN, the amount of expressed Myh9 was reduced to 23.5 ± 2.3% 
of the protein amount in Vav-iCre-/Myh9wt/fl (control) PMN. This was a greater reduction than 
expected for PMN with one remaining functional Myh9 allele. Hence, the possible 
significance of this downregulation of Myh9 expression for PMN trafficking was analysed in 
detail. 
 
 
3.2.1 In vitro studies using PMN from Myh9-cHet and control mice 
To study the maturation of control or Myh9-cHet PMN, the nuclear morphology and the 
expression of Ly6G, CXCR2 and CD11b was compared (Fig. 9). The mean fluorescence 
intensity of Ly6G, CXCR2 and CD11b as well as the morphology of the nucleus revealed no 
significant differences between control or Myh9-cHet PMN, suggesting that the maturation of 
PMN of control and Myh9-cHet mice was similar. 
 
 
Figure 9. Similar maturity of PMN from control (ctrl) and Myh9-cHet mice. 
(A) May-Grünwald-Giemsa staining of PMN. Depicted are representative microscopic 
images. Scale bar, 10 µm. (B) Flow cytometry analysis of PMN using specific, fluorescently 
labelled antibodies for Ly6G, CXCR2 and CD11b. n = 5 (adapted from Zehrer et al., 2018180). 
 
The effect of Myh9 knock-down for PMN trafficking was first investigated during spreading 
and polarisation of PMN on a rmICAM-1 and rmCXCL1 coated surface. No significant 
difference was found between control and Myh9-cHet PMN (Fig. 10A). Specifically, the area 
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and the circularity of PMN was comparable between both the control and the Myh9-cHet 
PMN, indicating that polarisation was not compromised upon downregulation of Myh9. To 
resist increasing shear stress forces, an effective activation of β2 integrins into the extended, 
high affinity formation is essential for PMN87. To examine the influence of Myh9 for this 
β2 integrin activation, control and Myh9-cHet PMN were allowed to adhere to immobilised 
rmICAM-1 and rmCXCL1 and increasing shear stress rates ranging from 0.5 up to 
8 dyne/cm2 were applied to the flow chamber. The percentage of adherent cells between 
control and Myh9-cHet PMN was calculated (Fig. 10B). Both the control and the Myh9-cHet 
PMN remained adherent throughout the observation time. Even at 8 dyne/cm2, nearly 100% 
of control and Myh9-cHet PMN were still adherent to the surface of the flow chamber, 
indicating no impact of reduced Myh9 on inducing the high affinity conformation of the 
β2 integrins.  
 
 
Figure 10. Reduced expression of Myh9 did not influence spreading or adhesion 
strengthening (A) Spreading of control (ctrl) and Myh9-cHet PMN upon exposure to 
immobilised rmICAM-1 and rmCXCL1 for 10 min in the absence of flow. Cell area and 
circularity were calculated from 3 independent experiments (n = 95 ctrl PMN, 
74 Myh9-cHet PMN). (B) Percentage of adherent PMN, relative to the amount of adherent 
PMN before the onset of flow, at indicated shear stress rates. Mean ± SEM, n = 3, n.s. not 
significant (adapted from Zehrer et al., 2018180). 
 
Next, the migration behaviour under flow conditions of control and Myh9-cHet PMN was 
analysed. The shape during migration under flow conditions, illustrated by the time-lapse 
images in Fig. 11A, appeared to be similar between control and Myh9-cHet PMN. Despite 
this, the quantitative analysis of the single cell migration tracks (Fig. 11B) demonstrated 
reduced migration velocity from 7.6 ± 0.15 µm/min in control PMN to 4.6 ± 0.03 µm/min in 
Myh9-cHet PMN. Euclidean distance was also reduced from 36.7 ± 1.6 µm for control PMN 
to 20.5 ± 1.6 µm for Myh9-cHet PMN (Fig 11C). Interestingly, this result was comparable to 
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the treatment with pn-blebbistatin, however the prominent phenotype with multiple 
pseudopods and an elongated cell shape was absent in Myh9-cHet PMN compared to 
pn-blebbistatin-treated PMN, suggesting a dose-dependent effect of Myh9 downregulation, 
which first compromises migration speed and only below a certain threshold the morphology 
of the migrating cells.  
 
 
Figure 11. Reduced expression of Myh9 caused defects in 2D migration under flow 
conditions in vitro. (A) Representative time-lapse images of migrating control (ctrl) and 
Myh9-cHet PMN under 1 dyne/cm2 shear stress on immobilised rmICAM-1 and rmCXCL1 at 
indicated time points. Scale bar, 10 µm. (B) Representative single cell migration tracks after 
10 min under 1 dyne/cm2 shear stress on immobilised rmICAM-1 and rmCXCL1. Arrows 
indicate direction of flow. (C) Migration velocity and Euclidean distance. n = 3 (322 ctrl 
PMN, 273 Myh9-cHet PMN. Mean ± SEM, n.s. not significant, ** p < 0.01, *** p < 0.001 
(adapted from Zehrer et al., 2018180). 
 
According to the consecutive steps in the PMN recruiting cascade, transmigration into the 
tissue is the next important step in the recruitment of PMN, following the migration along the 
vessel wall. Consequently, the PMN of control and Myh9-cHet mice were examined in two 
transmigration settings in vitro. The cells were allowed to transmigrate towards the 
chemoattractant rmCXCL1 through a membrane with 3 µm pores (Fig. 12A) or through a 
monolayer of bEnd.3 endothelial cells and an underlying membrane with a pore size of 8 µm 
(Fig. 12B). Successfully migrated PMN were counted and analysed. The experiments 
revealed that without the application of the stimulus, no difference in transmigration 
efficiency was observed between control and Myh9-cHet PMN. In this situation, 2.2 ± 0.9% 
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control and 3.6 ± 1.3% Myh9-cHet PMN transmigrated through the membrane pores and 
21.6 ± 4.4% control and 23.3 ± 4.5% Myh9-cHet PMN transmigrated through the endothelial 
coated 8 µm pores. Upon application of rmCXCL1, control PMN transmigrated successfully 
through the membrane pores as well as the bEnd.3 endothelial monolayer towards rmCXCL1 
(100%), whereas Myh9-cHet PMN transmigrated significantly less efficient in the presence of 
rmCXCL1, with only 40 ± 8.1% transmigrated Myh9-cHet PMN in case of the 3 µm pores 
and 49 ± 7% Myh9-cHet transmigrated PMN through the endothelial coated 8 µm pores 
compared to control PMN. These results indicated an important role for Myh9 during the 
process of transmigration of PMN. 
 
 
Figure 12. Diminished transmigration of PMN from Myh9-cHet mice in vitro. 
Quantitative analysis of transmigrated control (ctrl) and Myh9-cHet PMN towards a gradient 
of rmCXCL1 or without stimulus (-). Transmigrated PMN were normalized to ctrl PMN in 
the presence of rmCXCL1 (100%). (A) Transmigration through 3 µm pores. n = 3. (B) 
Transmigration through bEnd.3 endothelial cell coated 8 µm pores. n = 4. Mean ± SEM. n.s. 
not significant, *** p < 0.001 (adapted from Zehrer et al., 2018180). 
 
To investigate the impact of reduced Myh9 expression on the migration behaviour of PMN in 
fibrillar 3D environment, control and Myh9-cHet PMN were allowed to migrate in collagen 
networks towards the chemoattractant rmCXCL1 in vitro, mimicking interstitial migration 
towards sites of inflammation in vivo. Single cell migration tracks (Fig. 13A) of control and 
Myh9-cHet PMN in the collagen environment were compared and the associated parameters 
of migration velocity and Euclidean distance were analysed quantitatively (Fig. 13C). Here, 
control PMN displayed a mean velocity of 6.7 ± 0.43 µm/min and Myh9-cHet PMN had a 
significantly reduced migration velocity of 4.7 ± 0.37 µm/min. Also, the Euclidean distance 
was diminished in Myh9-cHet PMN compared to control PMN, from 33.7 ± 2.2 µm in control 
PMN to 23.4 ± 1.8 µm in Myh9-cHet PMN. To analyse the capacity of the control and 
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Myh9-cHet PMN to sense and orientate in the direction of the chemoattractant, rose plots 
(Fig. 13B) as well as the parameters directness (Euclidean distance divided by accumulated 
distance, indicating the straightness of migration) and forward migration index (end-position 
on x axis divided by accumulated distance, representing the efficiency of the forward 
migration towards the chemoattractant) (Fig. 13C) were employed. These criteria revealed 
that the reduction of Myh9 expression in Myh9-cHet PMN did not influence their ability to 
sense the rmCXCL1 gradient and to orientate migration in a specific direction.  
 
 
Figure 13. 3D migration in vitro was severely reduced in Myh9-cHet PMN. Migration in 
3D collagen networks (1.5 mg/mL) of control (ctrl) and Myh9-cHet PMN towards gradients 
of rmCXCL1 for 10 min. (A) Exemplary single cell migration tracks and (B) Rose plots. The 
area of each sector is proportional to the frequency of the migration vectors of tracked ctrl and 
Myh9-cHet PMN in the respective direction in response to gradients of rmCXCL1. Triangles 
indicate orientation of gradients. (C) Migration velocity and Euclidean distance as well as 
directness and forward migration index (x) (FMI). Mean ± SEM, n = 3 (441 ctrl and 386 
Myh9-cHet PMN). n.s. not significant, * p < 0.05 (adapted from Zehrer et al., 2018180). 
 
To decipher the mechanistic link between Myh9 downregulation and the observed migration 
defects, the subcellular localisation of Myh9 and F-actin during migration of control and 
Myh9-cHet PMN was analysed upon immunofluorescence staining of F-actin and Myh9 using 
STED nanoscopy. Control PMN localised their F-actin in the lamellipodium as well as in the 
trailing edge of the cells. Similarly, Myh9 was localised mainly in the leading edge and the 
uropod of the control PMN and colocalised at the front and back of the cells with F-actin 
(Fig. 14 left panel, merge). This distribution pattern stood in strong contrast to the observation 
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in Myh9-cHet PMN. Here, F-actin prevailed in the trailing edge of the PMN. Importantly, the 
Myh9 that was still expressed in Myh9-cHet PMN appeared to accumulate in one single spot, 
close to the rear of the cell with no apparent colocalisation with F-actin (Fig. 14 right panel, 
merge). These results indicated an impact of Myh9 expression on the subcellular localisation 
of Myh9 and F-actin during migration.  
 
 
Figure 14. Reduced Myh9 expression influenced subcellular localisation of Myh9 and 
F-actin during migration. STED nanoscopy images of migrating control (ctrl) and 
Myh9-cHet PMN on rmICAM-1 and rmCXCL1. Representative microscopic images (upper 
panel) and intensity profiles (lower panel) of F-actin and Myh9 along the segmented line 
through the representative PMN, of 8 control and 5 Myh9-cHet PMN. F-actin in magenta, 
Myh9 in cyan, merge in white. Scale bar, 10 μm, arrows indicate the front of the PMN 
(adapted from Zehrer et al., 2018180). 
 
To elucidate the influence of reduced Myh9 expression on the amount of expressed G-actin, 
the total amount of G-actin protein was compared between control and Myh9-cHet PMN 
using western blot. Here, no significant differences between the genotypes were detected 
(Fig. 15A). Next, the percentage distribution of F-actin and Myh9 to either the front or back 
of the PMN was analysed (Fig. 15 B, C). In control PMN 41.0 ± 4.1% of the F-actin intensity 
was found in the back of the cells and 57.0 ± 4.1% of the F-Actin intensity in the front of the 
cells. In Myh9-cHet PMN the F-actin distribution was 59.0 ± 8.0% in the back of the cells and 
37.5 ± 8.4% in the front of the cells. The distribution of Myh9 fluorescence intensity was in 
control PMN 40.5 ± 3.5% in the back of the cells and 57.0 ± 3.2% in the front of the cell. For 
Myh9-cHet PMN a Myh9 distribution with 57.7 ± 3.0% in the back of the cells and 
38.6 ± 3.6% in the front of the cells was detected. These quantitative results confirmed the 
observed shift of F-actin and Myh9 to the back of the cell in Myh9-cHet PMN compared to 
control PMN (Fig. 14 & 15 B/C), indicating a dysregulation in acto-myosin dynamics upon 
Myh9 downregulation.  
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Figure 15. Amount of Myh9 expression influenced Myh9-dependent F-actin distribution. 
(A) Actin expression in cell lysates from control (ctrl) and Myh9-cHet PMN. Protein 
expression was normalized to the amount of GAPDH protein expression (ctrl PMN 100%). 
n = 4 (B) F-actin and (C) Myh9 intensity distribution in percent in the back or the front of ctrl 
and Myh9-cHet PMN compared to total cell (100%). Total cell area was split equally into 
back and front. n = 8 for ctrl and n = 5 for Myh9-cHet PMN. (D) Randomization approach 
using the nearest-neighbour analysis with the MosaicIA interaction plugin of Fiji to analyse 
the dependence of F-actin localisation from Myh9 localisation. Exemplary distance 
distributions of the front of a ctrl and a Myh9-cHet PMN (Left and middle panel). Blue line, 
observed distance distribution between F-actin and Myh9. Green line, model fit of the 
observed distance distribution using a Plummer potential. Red line, probability density 
function (context) if F-actin was distributed randomly and independent of Myh9. 
F-actin/Myh9 interaction strength (right panel) in the front and back during migration. n = 4. 
Data represent mean ± SEM. * p < 0.05, ** p < 0.01 (adapted from Zehrer et al., 2018180). 
 
To investigate if F-actin distributes in dependence of Myh9, a statistical randomization 
approach was utilised (Fig. 15D). Here, the distance distribution of F-actin to Myh9 was 
graphically illustrated. In strong contrast to control PMN, upon Myh9 downregulation the 
observed distance distribution between F-actin and Myh9 in the front of the PMN (blue line), 
became similar to the probability density function (context, red line) representing F-actin 
distribution independent of Myh9. The curves were employed to calculate the interaction 
strength, indicating the degree of dependence between F-actin and Myh9 localisation. Values 
above 0 imply a spatial distribution of F-actin dependent of the spatial distribution of Myh9. 
The interaction strength of F-actin/Myh9 in the front of the cells was significantly different 
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between control and Myh9-cHet PMN with 7.8 ± 0.9 in control PMN and only 3.5 ± 0.9 in 
Myh9-cHet PMN180. These findings indicated that F-actin distribution was dependent on 
Myh9 localisation and that reduced expression of Myh9 restricted this interaction causing 
disturbed F-actin dynamics in the front of the cell, potentially impairing PMN migration.  
 
 
3.2.2 In vivo models using Myh9-cHet, control and bone marrow chimeric 
mice 
Despite the valuable in vitro experimental designs employed to study PMN trafficking, the 
situation in vivo often involves many unpredictable factors. Therefore, it is crucial to test the 
in vitro gained assumptions in an in vivo environment. First, the blood of control and 
Myh9-cHet mice was analysed for white blood cell (WBC) counts, along with the maturity of 
blood PMN between control and Myh9-cHet mice (Fig. 16). The comparison of WBC counts 
revealed no significant differences between the two genotypes in total WBC, PMN, 
lymphocytes, and monocytes (Fig. 16A). The analysis of the expression of the maturity 
markers Ly6G, CXCR2 and CD11b revealed similar expression of the three markers in 
control and Myh9-cHet PMN from the blood of these mice, indicating similar maturity of 
blood PMN in control and Myh9-cHet mice (Fig. 16B).  
 
 
Figure 16. Similar composition of white blood cells and maturity of blood PMN in 
control (ctrl) and Myh9-cHet mice. (A) White blood cell (WBC) counts. Lymph, 
lymphocytes; Mono, monocytes. n = 7 for ctrl and 9 for Myh9-cHet mice (B) Analysis of 
blood PMN by flow cytometry using specific, fluorescently labelled antibodies for expression 
of Ly6G, CXCR2 and CD11b. n = 5 (adapted from Zehrer et al., 2018180). 
 
To analyse the physiological relevance of Myh9 for PMN recruitment in vivo, two different 
models of acute inflammation were performed using Myh9-cHet and control mice. In the 
  Results 
61 
 
model of laser-induced sterile injury of the ear dermis, PMN recruitment is caused by a single 
necrotic lesion induced by focusing the laser beam to a single site in the murine ear. The 
tissue damage promotes PMN extravasation out of the vessel into the tissue and swarming 
towards the site of injury. Extravasation and interstitial migration were monitored using 
2-photon microscopy, FITC-dextran labelled vessels and Ly6G-PE-labelled PMN. For the 
analysis of the recorded videos, extravasation was determined using PE intensities within a 
circular area of interest, defined by the border of the laser injury to the border of the nearest 
vessel. Quantification was performed by calculating the fold change of the sum of intensity 
values, relative to the background intensity immediately after injury. During the observed 
time period of 40 min, a fold increase of PMN extravasation of 4.3 ± 1.6 compared to the 
starting time point with 1.0 ± 0.1 was recorded for control mice, but only a minimal number 
of PMN extravasated in Myh9-cHet mice, indicated by a fold increase from 1.0 ± 0.1 to 
0.9 ± 0.2 after 40 min (Fig. 17A). This significant reduction in extravasation of PMN in 
Myh9-cHet mice compared to control mice suggested an important role for Myh9 for 
extravasation of PMN in vivo. 
 
 
Figure 17. Transmigration and interstitial migration were severely impaired in a 
laser-induced injury model in the ear of Myh9-cHet mice. (A) Representative image of 
extravasation in a control mouse 40 min after induction of injury. Scale bar, 10 µm. PMN in 
pseudocolors, heat map = . (left panel). PMN extravasation evaluated as fold change of 
the sum of fluorescence intensity (FI) values compared to time-point 0, relative to the area 
between the two white circles, at indicated timeframes (right panel). (B) Migration velocity 
and Euclidean distance of interstitially migrating PMN. n = 5 for each mouse strain (≥10 
PMN per mouse). Mean ± SEM. n.s. not significant,* p < 0.05, ** p < 0.01, *** p < 0.001 
(adapted from Zehrer et al., 2018180). 
 
Additionally, PMN interstitially migrating towards the injury were analysed for their 
migration velocity and Euclidean distance during a 10 min time frame in control and 
Myh9-cHet mice (Fig. 17B). For PMN in control mice a migration velocity of 
7.2 ± 0.29 µm/min and an Euclidean distance of 55.3 ± 5.7 µm was determined. Myh9-cHet 
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PMN migrated with a significantly reduced velocity of 4.5 ± 0.21 µm/min and exhibited a 
diminished Euclidean distance of 33.6 ± 1.9 µm. The results of this injury model highlighted 
the importance of Myh9 for the extravasation process of PMN and demonstrated the relevance 
of Myh9 for interstitial migration in vivo. 
 
To confirm the in vivo trafficking defects of Myh9-cHet PMN, an additional model of acute 
inflammation was employed. In the rmCXCL1-induced peritonitis model the number of 
extravasated PMN into the peritoneal cavity was determined 4 h after intra-peritoneal 
injection of rmCXCL1 (Fig. 18). In control mice, 0.32 x 106 ± 0.12 PMN extravasated in the 
control situation with injection of 0.9% NaCl. Upon rmCXCL1 injection a profound 
extravasation of 3.25 x 106 ± 0.20 PMN was induced. On the other hand, in Myh9-cHet mice 
0.25 x 106 ± 0.13 PMN extravasated in the control situation, but only 0.82 x 106 ± 0.36 PMN 
were found in the peritoneal cavity after application of the stimulus. This significant reduction 
in extravasation after application of rmCXCL1 in Myh9-cHet mice compared to control mice 
highlighted the importance of an adequate Myh9 expression for an accurate recruitment of 
PMN. 
 
Figure 18. Diminished number of extravasated PMN into the peritoneal cavity in 
Myh9-cHet mice. Number of PMN in the peritoneal lavage 4 h after intra-peritoneal injection 
of 0.9% NaCl or 300 ng rmCXCL1 in control (ctrl) or Myh9-cHet mice. Data represents mean 
with individual data points, n = 3. n.s. not significant, *** p < 0.001 (adapted from Zehrer et 
al., 2018180). 
 
To study whether the observed migration defects were cell-intrinsic, three different models of 
bone marrow chimeras were set up (Fig. 19A). To distinguish between donor and recipient 
cells, the CD45.1/2 system was applied. In the first model, serving as control, CD45.1 
expressing wildtype bone marrow cells were transplanted in lethally irradiated CD45.1 
expressing wildtype mice (WT→WT). The second model involved the transplantation of 
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CD45.2 expressing Myh9-cHet bone marrow cells into CD45.1 expressing wildtype mice 
(HET→WT). In the third model, a 1:1 ratio of CD45.1 wildtype and CD45.2 Myh9-cHet bone 
marrow cells were transferred into CD45.1 expressing wildtype mice (MIX→WT).  
 
 
Figure 19. Successful generation of bone marrow chimeras. (A) Schematic of bone 
marrow transfer models (B) White blood cell (WBC) counts. Lymph, lymphocytes; Mono, 
monocytes. (C) Distribution of CD45.1 and CD45.2 positive blood PMN in the three models. 
n ≥ 5 (adapted from Zehrer et al., 2018180).  
 
After a recovery time of 6 weeks, successful engraftment of donor cells was investigated by 
analysing the blood of the chimeras for WBC counts and the percentage of CD45.1 or CD45.2 
expressing PMN (Fig. 19B, C)180. Here, comparable numbers of lymphocytes and monocytes 
were found in all three models. The counts for PMN and consequently total WBC were 
slightly elevated in the HET→WT mice, but similar in the WT→WT and MIX→WT models. 
In the case of successful generation of bone marrow chimeric mice, 100% CD45.1 positive 
PMN in the WT→WT model, 100% CD45.2 positive PMN in the HET→WT model and a 
50%/50% proportion of CD45.1 and CD45.2 positive PMN in the MIX→WT model were 
expected. In this study, all PMN were CD45.1 positive in the WT→WT model, while in the 
HET→WT model, only 3% of the PMN were of recipient origin and CD45.1 positive, 
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whereas 97% were of donor origin and CD45.2 positive. In the MIX→WT model, the 
distribution was determined to be 48% CD45.1 and 52% CD45.2 positive PMN (Fig. 19C). 
Thus, the distribution of CD45.1 and CD45.2 amongst the PMN in the blood was as expected 
and indicated successful engraftment of donor cells in the irradiated recipient mice.  
 
To investigate PMN recruitment in the chimera models, the rmCXCL1-induced peritonitis 
model was employed. The number of extravasated PMN into the peritoneal cavity was 
determined 4 h after intra-peritoneal injection of rmCXCL1 (Fig. 20A). In the WT→WT 
control model, 0.90 x 106 ± 0.45 PMN were detected in the peritoneal cavity upon injection of 
0.9% NaCl, whereas upon rmCXCL1 injection a profound extravasation of 4.86 x 106 ± 0.49 
PMN was induced. In contrast, in the HET→WT model, 0.03 x 106 ± 0.03 PMN extravasated 
upon injection of 0.9% NaCl, and only 3.27 x 106 ± 0.21 PMN extravasated after application 
of the stimulus. In the MIX→WT mice 0,60 x 106 ± 0.45 PMN were detected in the peritoneal 
cavity in the control situation. Interestingly, the extravasation of PMN in the peritoneal cavity 
upon rmCXCL1 application was comparable to that observed in the HET→WT mice, with 
3.21 x 106 ± 0.40 PMN.  
 
 
Figure 20. Diminished number of extravasated PMN into the peritoneal cavity in 
HET→WT and MIX→WT chimeric mice. (A) Number of PMN in the peritoneal lavage 4 
h after intra-peritoneal injection of 0.9% NaCl or 300 ng rmCXCL1 in WT→WT, HET→WT 
and MIX→WT chimeric mouse models. Data represents mean with individual data points (B) 
Distribution of CD45.1 and CD45.2 positive extravasated PMN in the three models. Data 
represents mean ± SEM, n = 2 for NaCl, n ≥ 4 for rmCXCL1. * p < 0.05 (adapted from Zehrer 
et al., 2018180). 
 
The analysis of CD45.1 and CD45.2 distributions in the extravasated PMN pool revealed an 
unchanged pattern in the blood of the mice (compare Fig. 19C and 20B). These results 
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suggest a cell-intrinsic migration defect in PMN upon Myh9 downregulation as the presence 
of wildtype PMN could not rescue the extravasation defect in the MIX→WT mice. 
Furthermore, the reduced extravasation in HET→WT mice confirmed the observations with 
the control and Myh9-cHet mice. 
 
 
3.3 Hoxb8- SCF cell-derived neutrophils - a tool to study PMN trafficking 
3.3.1 Generation and differentiation of Hoxb8-SCF cells 
As PMN are especially short-lived cells and therefore not genetically manipulable, PMN 
research often relied on pharmacological inhibitor studies. During the last decade, a new 
murine cell system has been developed, based on the immortalisation of murine hematopoietic 
progenitor cells using an estrogen-dependent variant of the transcription factor Hoxb8 
(ER-Hoxb8). The Hans Häcker group described that, upon estrogen binding, the ER-Hoxb8 
fusion protein translocates to the nucleus and induces the transcription of all proteins 
necessary to prevent differentiation of the progenitor cells197,198. Upon estrogen removal, the 
ER-Hoxb8 becomes inactive and the progenitor cells differentiate. During the generation of 
the Hoxb8 cell line, growth factors influence the type of progenitor cells produced. Lymphoid 
primed multipotent progenitors (LMPP) can be generated using Flt3L, whereas SCF drives 
the cells towards granulocyte-macrophage progenitors (GMP)198. During the process of 
differentiation, the addition of growth factors also plays an import role, as they determine the 
cell type the progenitors differentiate into. In this study, Hoxb8-SCF cells with the potential to 
differentiate towards PMN and macrophages were generated from hematopoietic progenitor 
cells in murine bone marrow or foetal livers and differentiation towards PMN was initiated by 
the removal of estrogen and the presence of SCF and G-CSF.  
 
To establish Hoxb8-SCF cell-derived neutrophils as a tool to study PMN trafficking, the 
optimisation of the differentiation process including the selection of the optimal length was 
crucial. Therefore, Hoxb8-SCF cells were allowed to differentiate for 6 days, with samples 
taken at day 0, 3, 4, 5, and 6, to be analysed for their percentage of viable cells, as well as the 
expression of CD11b and Ly6G, two key makers of murine PMN differentiation (Fig. 21). 
The results demonstrated that these extracellular markers were barely detectable on 
undifferentiated Hoxb8-SCF cells at day 0, but expression was induced upon differentiation, 
with Ly6G increasing continuously over the observed period of time (Fig. 21B). Importantly, 
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the viability of the Hoxb8-SCF cells was found to decrease rapidly after day 4 of 
differentiation (Fig. 21A). Consequently, day 4, with 76.7 ± 1.2% of viable cells and 
considerable expression of CD11b and Ly6G was chosen as the endpoint of differentiation for 
this study.  
 
 
Figure 21. CD11b and Ly6G expression got induced in viable Hoxb8-SCF cells upon 
differentiation. Hoxb8-SCF cells were differentiated for the indicated days by removal of 
estrogen and addition of G-CSF. (A) Amount of living Hoxb8-SCF cells in percent, 
determined using PI staining. (B) Expression of CD11b and Ly6G analysed at indicated days 
by flow cytometry using specific, fluorescently labelled antibodies. Mean fluorescence 
intensity corrected by isotype control. n = 3. Mean ± SEM. 
 
Undifferentiated (d0) and differentiated (d4) Hoxb8-SCF cells were subsequently 
characterised for their phenotypic appearance (Fig. 22). May-Grünwald-Giemsa staining 
confirmed a large, unsegmented nucleus in the progenitor cells, whereas after 4 days of 
differentiation the Hoxb8-SCF cells were reduced in size and the nucleus altered to the 
segmented shape typically observed in PMN (Fig. 22A). Comparison of extracellular markers 
between d0, d4 and murine bone marrow-derived PMN confirmed that Hoxb8-SCF cells 
downregulated the progenitor markers CD34, Flt3 and c-kit during differentiation to similar 
levels as in PMN (Fig. 22B). Murine PMN maturity markers Gr-1, Ly6G and CXCR2 were 
absent in d0 Hoxb8-SCF progenitor cells, yet were strongly induced in d4 Hoxb8-SCF cells 
and were also present in PMN (Fig 22C). The analysis of integrin expression revealed that 
LFA-1 (CD11a/CD18) was similarly expressed in d0, d4 Hoxb8-SCF cells and PMN, whereas 
CD11b was barely expressed in undifferentiated d0 Hoxb8-SCF cells and highly expressed in 
d4 Hoxb8-SCF cells and PMN. The integrin subunit CD11c was absent in all three tested cell 
types, confirming the absence of CD11c expressing cell types, like dendritic cells (Fig. 22D). 
This data suggests a very similar phenotype between d4 Hoxb8-SCF cells and murine bone 
marrow-derived PMN.  
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Figure 22. Differentiation profile of Hoxb8-SCF cells before and after removal of 
estrogen for 4 days. Undifferentiated (d0) Hoxb8-SCF cells, differentiated for 4 days with 
SCF and G-CSF towards PMN (d4) (A) Stained with May-Grünwald-Giemsa. Depicted are 
representative microscopic images. Scale bar, 10 µm. (B-D) D0 and d4 Hoxb8-SCF cells, as 
well as murine bone marrow-derived PMN were analysed by flow cytometry using specific, 
fluorescently labelled antibodies for expression of differentiation markers. (B) CD34, Flt3, 
and c-kit, (C) Gr-1, Ly6G, and CXCR2 and (D) CD11a, CD11b, CD11c, and CD18. Mean 
fluorescence intensity corrected by isotype control. n = 3. Mean ± SEM. * p < 0.05 (adapted 
from Zehrer et al., 2018180). 
 
 
3.3.2 Functional characterisation of Hoxb8-SCF cell-derived neutrophils 
To employ Hoxb8-SCF cell-derived neutrophils as a tool to study the processes involved in 
PMN trafficking, the cells not only have to have a phenotype similar to PMN, but must also 
behave similar to PMN in various experimental conditions. Upon stimulation, PMN quickly 
upregulate the integrins CD11b and CD18. These are stored in secondary, peroxidase-
negative, granules to be immediately available for presentation at the cell surface when the 
PMN is activated33.To determine whether Hoxb8-SCF cells are able to react upon stimulation 
with upregulation of surface CD11b and CD18, d0 and d4 Hoxb8-SCF cells were stimulated 
with PMA, rmCXCL1, rmTNFα, or fMIVIL and cell surface expression of the integrins 
CD11b, CD18 and CD11a was analysed using flow cytometry (Fig. 23). Undifferentiated d0 
Hoxb8-SCF progenitor cells, as expected, did not react upon stimulation by upregulation of 
integrins, rather they maintained the expression of CD18 and CD11a at the basal level 
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described previously (Fig. 22D). However, d4 Hoxb8-SCF cells significantly increased 
CD11b and CD18 at the cell surface upon interaction with all tested stimuli compared to the 
controls. In contrast, the expression of CD11a, was not affected by stimulation, as expected 
(Fig. 23)33,34. 
 
 
 
Figure 23. Upregulation of Mac-1 in d4 Hoxb8-SCF cells after stimulation. Hoxb8-SCF 
cells before (d0) and after (d4) removal of estrogen were stimulated with 100 nM PMA, 
100 ng/mL rmCXCL1, 100 ng/mL rmTNFα, 100 nM fMIVIL, or left untreated (-) for 
negative control. CD11b, CD18 and CD11a cell surface expression was analysed using flow 
cytometry using specific, fluorescently labelled antibodies. Mean fluorescence intensity 
corrected by isotype control. n = 3. Mean ± SEM. * p < 0.05 unstimulated vs. stimulated 
(adapted from Zehrer et al., 2018180). 
 
After upregulation and activation of integrins, PMN have the potential to adhere to surfaces 
via their integrins. Hence, the ability of Hoxb8-SCF cells to induce adhesion was investigated 
under static and flow conditions in vitro (Fig. 24). Under static conditions d0 and d4 
Hoxb8-SCF cells were allowed to adhere after stimulation with PMA, rmCXCL1, rmTNFα, 
or fMIVIL and the result was calculated in fold induction of adhesion compared to 
unstimulated conditions (Fig. 24A). In accordance to the basal expression of CD11a and 
CD18 in d0 Hoxb8-SCF cells, these progenitor cells adhered to ICAM-1 coated surfaces 
when stimulated with the non-physiological stimulator PMA or the inflammatory mediator 
rmTNFα. As binding of mfibrinogen requires CD11b, the d0 Hoxb8-SCF cells were not able 
to induce adhesion on this surface, as expected. However, d4 Hoxb8-SCF cells were found to 
adhere after incubation with all tested stimuli on rmICAM-1, and after incubation with PMA, 
rmCXCL1 and fMIVIL on mfibrinogen (Fig. 24A). The efficiency for induction of adhesion 
under flow conditions was directly compared between d4 Hoxb8-SCF cells and murine bone 
marrow-derived PMN. Cell counts for rolling and adherent cells on immobilised rmP-selectin, 
rmICAM-1 and rmCXCL1 were determined at five different time-points during the assay 
(Fig. 24B, left panel). No significant difference was observed between PMN and 
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d4 Hoxb8-SCF cells during this time-course, indicating that the behaviour of the two cell 
types is highly comparable in this experiment. Furthermore, the specificity of adhesion of the 
d4 Hoxb8-SCF cells was tested by repeating the assay without immobilised rmCXCL1 (Fig. 
24B, right panel). As expected, the number of rolling cells was significantly increased from 
22 ± 8, in the presence of rmCXCL1, to 235 ± 51, in the absence of rmCXCL1. The number 
of adherent cells was strongly diminished from 445 ± 60, in the presence of rmCXCL1, to 195 
± 69, in the absence of rmCXCL1. Hence, the induction of adhesion of d4 Hoxb8-SCF cells 
occurred specificly through activation of the cells by rmCXCL1. 
 
 
Figure 24. Induction of adhesion of Hoxb8-SCF cells. (A) D0 and d4 Hoxb8-SCF cells on 
immobilised rmICAM-1 or mfibrinogen were stimulated under static conditions using 
100 ng/mL rmTNFα, 100 ng/mL rmCXCL1, 3 mM Mn2+, 100 nM PMA, or 100 nM fMIVIL, 
or left untreated (-) for negative control. Adherent cells were normalized to untreated d0, or 
d4 Hoxb8-SCF cells respectively. n = 3. * p < 0.05. (B) Numbers of rolling and adherent cells 
of d4 Hoxb8-SCF cells or murine bone marrow-derived PMN under 1 dyne/cm2 of flow on 
immobilised rmP-selectin, rmICAM-1 and rmCXCL1 (left panel) at indicated time points and 
(right panel) after 9 min with rmCXCL1 stimulation or without for control. n = 4. Mean ± 
SEM. n.s., not significant (d4 Hoxb8-SCF cells to PMN adherent cells), * p < 0.05 (adapted 
from Zehrer et al., 2018180). 
 
After successful adhesion, PMN start to migrate along blood vessel walls. To mimic this 
process in vitro, d4 Hoxb8-SCF cells were allowed to migrate on immobilised rmICAM-1 and 
rmCXCL1 under 1 dyne/cm2 of shear stress (Fig. 25A). Single cell migration tracks were 
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analysed for migration velocity and Euclidean distance. Rose plots were used to determine the 
distribution of migration directions. With a mean migration velocity of 4.19 ± 0.51 µm/min 
and an Euclidean distance of 24.8 ± 2.66 d4 Hoxb8-SCF migrate with less than half the speed 
and distance compared to what was previously described for murine PMN under flow 
conditions (Fig. 25A)104,187. However, d4 Hoxb8-SCF cells were able to migrate directionally, 
as well as against and perpendicular to the direction of flow, identical to what is described for 
murine PMN186,187. When exposed to a chemotactic gradient of rmCXCL1 in the 2D 
environment of a Zigmond chamber, d4 Hoxb8-SCF cells migrated with a mean velocity of 
5.5 ± 0.1 µm/min preferentially in the direction of the higher concentration of the 
chemoattractant rmCXCL1, as determined by single cell migration tracks and the 
corresponding rose plots (Fig. 25B). Thus, the behaviour of d4 Hoxb8-SCF cells in the 
presence of shear stress and chemotactic gradients underline the similarity of d4 Hoxb8-SCF 
cells to murine bone marrow-derived PMN and further prove their suitability as a tool to study 
PMN trafficking.  
 
 
Figure 25. Mechanotactic and chemotactic migration of d4 Hoxb8-SCF cells. 
(A) Mechanotactic migration on immobilised rmICAM-1 and rmCXCL1 under 1 dyne/cm2 of 
flow for 10 min. Representative single cell migration tracks and rose plot with indicated mean 
migration velocity (ν) and Euclidean distance (d(x/y)). Arrows indicate direction of flow. 
n = 3 (206 d4 Hoxb8-SCF cells). (B) Chemotactic migration of d4 Hoxb8-SCF cells on 
immobilised rmICAM-1 in Zigmond chambers towards a gradient of rmCXCL1 for 10 min. 
Triangles indicate orientation of gradients. Representative single cell migration tracks and 
rose plot with indicated mean migration velocity (ν) and Euclidean distance (d(x/y)). n = 3 
(479 d4 Hoxb8-SCF cells), (adapted from Zehrer et al., 2018180).  
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3.4 Migration of Myh9-EGFP expressing Myh9-knock-down Hoxb8-SCF 
cell-derived neutrophils 
3.4.1 Generation of Hoxb8-SCF cells from Vav-iCre-/Myh9fl/fl, Vav-iCre+ 
/Myh9wt/fl, and Vav-iCre+/Myh9fl/fl foetal liver progenitor cells  
To perform rescue experiments, a Myh9-EGFP fusion protein should be expressed in cells 
with a knock-down in Myh9 expression. As the d4 Hoxb8-SCF cells were successfully 
evaluated as a suitable tool to study PMN trafficking, the Hoxb8-SCF cells system was 
employed for this task. Hoxb8-SCF cells were generated from foetal liver progenitor cells of 
E13 embryos with a Vav-iCre-/Myh9fl/fl, Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl genotype. 
The discovery of embryos, but no viable pups, with the Vav-iCre+/Myh9fl/fl genotype, 
suggested that mice with this genotype die between E13 during embryogenesis and birth.  
 
 
Figure 26. Myh9 expression in Hoxb8-SCF cells generated from foetal liver progenitor 
cells. (A) Representative western blot of Myh9 expression in cell lysates from foetal liver 
Hoxb8-SCF d0 and d4 cells derived from Vav-iCre-/Myh9fl/fl mice and Myh9 knock-down 
Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl mice. (B) Quantitative analysis of Myh9 protein 
expression. Protein expression of Myh9 was normalized to GAPDH and d4 Hoxb8-SCF 
Vav-iCre-/Myh9fl/fl cells (100%). n ≥ 3 (C) Flow cytometry histograms of intracellularly 
stained Myh9 in d4 Hoxb8-SCF cells and isotype controls. (D) Quantification of mean 
fluorescence intensities (MFI) normalized to Vav-iCre-/Myh9fl/fl cells (100%). n = 3: Mean ± 
SEM. n.s. not significant, *** p < 0.001 (adapted from Zehrer et al., 2018180).  
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To determine the amount of Myh9 protein expressed in these Hoxb8-SCF cell lines, western 
blotting was performed using cell lysates of Hoxb8-SCF progenitor cells and d4 Hoxb8-SCF 
cells (Fig. 26A). Unexpectedly, quantification of normalized Myh9 expression revealed that 
the expression of Myh9 in the undifferentiated Hoxb8-SCF cells was similar between the 
three genotypes. During differentiation to PMN, control Hoxb8-SCF cells with a       
Vav-iCre-/Myh9fl/fl genotype increased their Myh9 expression drastically, whereas 
Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl Hoxb8-SCF cells failed to increase their Myh9 
levels significantly, resulting in a diminished expression of Myh9 in these d4 Hoxb8-SCF 
cells, with 38.7 ± 4.9% for Vav-iCre+/Myh9wt/fl and 35.4 ± 1.7% for Vav-iCre+/Myh9fl/fl 
compared to Vav-iCre-/Myh9fl/fl d4 Hoxb8-SCF cells (100%, Fig. 26B). To investigate the 
expression of Myh9 throughout the populations on a single cell niveau, flow cytometry of 
intracellular stained Myh9 was performed. Comparison of the histograms for Myh9 in 
Vav-iCre-/Myh9fl/fl, Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl d4 Hoxb8-SCF cells, allowed 
an exclusion of heterogeneity within the single populations (Fig. 26C). Quantification of the 
mean fluorescence intensity values confirmed the significant downregulation of Myh9 
determined using western blots in Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl compared to 
Vav-iCre-/Myh9fl/fl d4 Hoxb8-SCF cells (Fig. 26D).  
 
The unexpected similar amounts of Myh9 protein in Vav-iCre+/Myh9wt/fl and 
Vav-iCre+/Myh9fl/fl d4 Hoxb8-SCF cells demanded further investigation of the genetic 
processes occurring in these cells. Therefore, an additional PCR was performed. In contrast to 
the originally described genotyping PCR, the forward primer was designed in front of the 
5’ flox region of the Myh9 exon 1. The reverse primer used was in the same position as in the 
originally described genotyping PCR and located after the 3’ flox region (Fig. 4, methods 
section). With this new approach wildtype alleles (Myh9wt) as well as floxed alleles (Myh9fl), 
and alleles where the Cre recombinase deleted exon 1 (Myh9del), could be visualized and 
distinguished. In Fig. 27A, the original genotyping PCR of the E13 embryos for Vav-iCre and 
floxed Myh9 is displayed and demonstrates the indicated genotypes. The results of the 
additionally performed PCR are depicted in Fig. 27B. In the case of the control 
Vav-iCre-/Myh9fl/fl Hoxb8-SCF cells, one band for the Myh9fl allele was visible, as expected. 
For Vav-iCre+/Myh9wt/fl Hoxb8-SCF cells, a band for the Myh9wt and a band for Myh9del were 
found, as expected for hematopoietic cells with active Cre recombinase. Interestingly, in 
Vav-iCre+/Myh9fl/fl Hoxb8-SCF cells, a band for Myh9fl was still present as additionally 
verified by sequencing, but a strong band for Myh9del was also visible. In combination with 
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the flow cytometry data, this led to the hypothesis that in the pool of Vav-iCre+/Myh9fl/lf 
Hoxb8-SCF cells, a population with less effective Cre recombination, and therefore only one 
Myh9del allele, had a tremendous selection advantage during proliferation resulting in a 
heterozygous phenotype of the Vav-iCre+/Myh9fl/fl d4 Hoxb8-SCF cells. 
 
 
Figure 27. Genotyping PCRs of the Myh9 exon 1 locus (A) Original genotyping of 
Vav-iCre and Myh9 loci for Myh9fl and Myh9wt, and Vav-iCre+. (B) Additional PCR of the 
Myh9 locus for Myh9fl, Myh9wt and Myh9del in d0 and d4 Hoxb8-SCF cells. Images are 
representative of 3 independent experiments (adapted from Zehrer et al., 2018180).  
 
To exclude the possibility that the reduced amount of Myh9 protein in Hoxb8-SCF cells 
interferes with the differentiation process towards PMN, Vav-iCre-/Myh9fl/fl, 
Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl d0 and d4 Hoxb8-SCF cells were analysed for 
their expression of surface progenitor markers, PMN markers and integrin expression using 
flow cytometry. The progenitor markers CD34 and c-kit were found to be expressed in all 
three cell lines before differentiation (d0) and were strongly downregulated after their 
differentiation towards PMN (d4) (Fig. 28A). On the other hand, Gr-1, Ly6G and CXCR2 
were barely expressed in all three d0 Hoxb8-SCF cells lines and, as expected, were 
upregulated upon differentiation (Fig. 28B). The analysis of integrin expression revealed that 
CD11a was similarly expressed between all three genotypes and independent of 
differentiation. In contrast, CD11b was barely expressed in d0 Hoxb8-SCF cells and highly 
expressed in d4 Hoxb8-SCF of all genotypes, as expected. The integrin subunit CD11c was 
absent in all three tested cell lines and time points, confirming the absence of CD11c 
expressing cell types, like dendritic cells. Also, CD18 was found to be expressed in d0 
Hoxb8-SCF cells and was upregulated in all three genotypes upon differentiation, as expected 
(Fig. 28C). This data suggests that the differentiation process towards PMN was equally 
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successful in Vav-iCre-/Myh9fl/fl and Vav-iCre+/Myh9fl/fl, as well as Vav-iCre+/Myh9wt/fl 
Hoxb8-SCF cells.  
 
 
Figure 28. Differentiation profile of foetal liver-derived Hoxb8-SCF cells. D0 and d4 
Hoxb8-SCF cells from Vav-iCre-/Myh9fl/fl as well as from Vav-iCre+/Myh9wt/fl and 
Vav-iCre+/Myh9fl/fl embryos were analysed by flow cytometry using specific, fluorescently 
labelled antibodies for expression of differentiation markers. (A) CD34 and c-kit, (B) Gr-1, 
Ly6G, and CXCR2 and (C) CD11a, CD11b, CD11c, and CD18. Mean fluorescence intensity 
corrected by isotype control. n = 4. Mean ± SEM. * p < 0.05. 
 
 
3.4.2 Generation of a Myh9-EGFP expressing Hoxb8-SCF cell line  
Before the generation of a Myh9-EGFP expressing Hoxb8-SCF cell line, the functionality of 
the #38297 pMyosin-II-A-GFP plasmid was confirmed by transfection of HEK-293T cells 
with the plasmid. Expression of the Myh9-EGFP fusion protein was analysed using confocal 
microscopy (Fig. 29A). Myh9-EGFP was visible and colocalised with F-actin, as expected. 
For successful introduction of the EGFP-MyosinII-A DNA into Hoxb8-SCF cells, retroviral 
transduction was selected. Therefore, EGFP-MyosinII-A was cloned into the retroviral 
backbone pMSCV-Puro proceeding as displayed in Fig. 29B. Primers including restriction 
sites and 15 bp, overlapping with the backbone, were designed to amplify the region of 
interest from the pMyosin-II-A-GFP. Using the In-Fusion ligase mix, the EcoRI / XhoI 
opened pMSCV-Puro was linked with the PCR fragment. Transformation into competent 
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bacteria ensured the amplification of the plasmid. In the next step, the purified plasmid was 
cut with EcoRI to identify successfully ligated MSCV-Puro-Myosin-II-A-GFP plasmids by an 
additionally appearing band (Fig. 29C lane B) in contrast to a linearized empty backbone 
(Fig. 29C lane A). 
 
 
Figure 29. Generation of pMSCV-Puro-Myosin-II-A-GFP. (A) Microscopy of two 
HEK-293T cells. One cell successfully transfected with pMyosin-II-A-GFP (turquoise, left 
picture), F-actin staining in both cells (magenta, middle picture) and colocalisation of Myh9 
and F-actin in the one Myh9 expressing cell (merge, white, right picture) Representative 
images of 2 independent experiments. Scale bar, 10 µm (adapted from Zehrer et al., 2018180). 
(B) Schematic for the generation of pMSCV-Puro-Myosin-II-A-GFP. (A) The retroviral 
backbone pMSCV-Puro was opened using EcoRI and XhoI restriction enzymes. Myh9-EGFP 
was extracted from the expression plasmid by PCR using primers including the restriction site 
for EcoRI or XhoI, and additionally overlapping sequences with the pMSCV-Puro vector. 
These compatible ends enable recombination and fusion of the two linearized DNA strands in 
the In-Fusion cloning reaction to the MSCV-Puro-pMyosin-II-A-GFP plasmid. (B) Successful 
cloning was confirmed by control digest with EcoRI. The two expected bands with 9.174 bp 
and 3.786 bp, can be seen in lane B of the representative image. 
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The MSCV-Puro-Myosin-II-A-GFP vector was sequenced (data not shown) and further used 
to generate retrovirus encoding for Myh9-EGFP. Vav-iCre+/Myh9fl/fl Hoxb8-SCF cells were 
defined as knock-down (KD) cells and transduced with the virus. After Puromycin selection, 
successful transduction was confirmed via flow cytometry (Fig. 30A). Subsequently, EGFP 
positive cells were sorted from the Hoxb8-SCF cell pool (Fig. 30A). To confirm the 
expression of the fusion protein, western blotting for EGFP and Myh9 was performed using 
lysates of the sorted Hoxb8-SCF cell population and non-transduced Myh9-KD Hoxb8-SCF 
cells (Fig. 30B). As expected, endogenous Myh9 was detected in undifferentiated and 
differentiated Myh9-KD cells, whereas the fusion protein Myh9-EGFP was only identified in 
the transduced undifferentiated and differentiated Myh9-KD Hoxb8-SCF cells. These cells 
were defined as Myh9-RES Hoxb8-SCF cells.  
 
 
Figure 30. Generation of Myh9-EGFP expressing Myh9 kock-down (KD) Hoxb8-SCF 
cells. (A) Flow cytometry for EGFP intensity in foetal liver Myh9-KD-Hoxb8-SCF cells, 
before (left panel) and after transduction (middle panel) with pMSCV-Puro-Myosin-II-A-GFP, 
as well as after sorting for EGFP positive cells (right panel). Numbers indicate percent of total 
cells analysed (100%) in each panel. (B) Representative western blot indicating the expression 
of Myh9-EGFP (green) in transduced Myh9-KD Hoxb8-SCF cells (Myh9-RES Hoxb8-SCF 
cells, RES) before and after differentiation. Endogenous Myh9 expression (red) in Myh9-KD 
Hoxb8-SCF cells (KD) and Myh9-RES Hoxb8-SCF cells (RES). Overlapping signal of Myh9-
EGFP (green) and endogenous Myh9 (red) presented as merge (yellow) (adapted from Zehrer 
et al., 2018180). 
 
 
3.4.3 Rescue of migration in Myh9-RES Hoxb8-SCF cells  
To investigate the potential rescue function of the introduced fusion protein, the migratory 
capacity of Vav-iCre-/Myh9fl/fl (control), Vav-iCre+/Myh9wt/fl (Myh9-cHet), Vav-iCre+/Myh9fl/fl 
(Myh9-KD) and Myh9-RES Hoxb8-SCF cell-derived neutrophils (dHoxb8 cells) was analysed 
in a 2D environment using 1 dyne/cm2 shear stress on immobilised rmICAM-1 and 
rmCXCL1. Single cell migration tracks revealed a longer migrated distance for control and 
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Myh9-RES dHoxb8 cells in comparison to Myh9-KD and Myh9-cHet dHoxb8 cells (Fig. 
31A). This finding was confirmed by quantitative analysis of the migration velocity and the 
Euclidean distance (Fig. 31B). Specifically, control and Myh9-RES dHoxb8 cells reached 
mean velocities of 3.7 ± 0.2 and 3.3 ± 0.5 µm/min SEM, whereas Myh9-KD and Myh9-cHet 
dHoxb8 cells migrated significantly slower with 1.9 ± 0.1 and 2.4 ± 0.1 µm/min. The same 
picture emerged when the Euclidean distance was compared. Here, control and Myh9-RES 
dHoxb8 cells exhibited an Euclidean distance of 19.4 ± 2.1 µm SEM and 19.4 ± 1.7 µm, 
whereas the Euclidean distance in Myh9-KD and Myh9-cHet dHoxb8 cells was significantly 
lower with 8.8 ± 0.4 and 12.0 ± 0.2 µm (Fig. 31B). These results were in line with the 
experimental outcomes for bone marrow-derived PMN of control and Myh9-cHet mice, 
where Myh9-cHet PMN displayed reduced migratory capacity in a 2D environment. 
Furthermore, these results proved that the introduced Myh9-EGFP fusion protein rescued the 
2D migration defect observed in Myh9-KD dHoxb8 cells. 
 
 
Figure 31. Expression of Myh9-EGFP in Myh9-KD dHoxb8 cells rescued migratory 
defects in 2D environment. (A) Single cell migration tracks of control (ctrl), Myh9-KD, 
Myh9-cHet and Myh9-RES dHoxb8 cells after 10 min under shear stress of 1 dyne/cm2 on 
immobilised rmICAM-1 and rmCXCL1. Arrows indicate direction of flow. Displayed are 
single cell migration tracks of representative experiments. (B) Quantitative analysis of 
migration velocity and Euclidean distance. Mean ± SEM, n > 3 (395 ctrl, 734 Myh9-KD, 268 
Myh9-cHet and 233 Myh9-RES dHoxb8 cells). n.s. not significant, *p < 0.05, ** p < 0.01, 
*** p < 0.001, ### p < 0.001 compared to Myh9-KD dHoxb8 cells (adapted from Zehrer et 
al., 2018180). 
 
  Results 
78 
 
To investigate whether Myh9-RES cells also benefit from the introduced Myh9-EGFP fusion 
protein in a 3D environment, Myh9-KD and Myh9-RES dHoxb8 cells were allowed to migrate 
in a 1.5 mg/mL collagen gel towards a gradient of rmCXCL1. On the basis of single cell 
migration tracks and rose plots, it was found that both cell types sensed and orientated 
towards the gradient (Fig 32A and B). This was confirmed quantitatively using the parameters 
directness and forwards migration index in x direction (Fig. 32C). Here, no significant 
difference was detected between Myh9-KD and Myh9-RES dHoxb8 cells. The positive values 
for the migration index in x direction confirmed migration in the direction of the increasing 
rmCXCL1 concentration. In contrast to this, Myh9-KD dHoxb8 cells were significantly 
slower and migrated less far than the Myh9-RES dHoxb8 cells (Fig. 32A, C): Myh9-KD cells 
exhibited 22.5 ± 3.4 µm Euclidean distance with a velocity of 4.3 ± 0.6 µm/min, whereas the 
introduced Myh9-EGFP increased the migratory capacity of Myh9-RES cells to 37 ± 2.6 µm 
Euclidean distance and 6.2 ± 0.2 µm/min migration velocity. It was concluded that Myh9-RES 
dHoxb8 cells indeed benefitted from the introduced Myh9-EGFP in terms of migration speed 
and distance, compared to Myh9-KD dHoxb8 cells in 3D environment.  
 
 
Figure 32. Migration behaviour in 3D environment was recovered by the expression of 
Myh9-EGFP in Myh9-KD dHoxb8 cells. Migration in 3D collagen networks (1.5 mg/mL) of 
Myh9-KD and Myh9-RES dHoxb8 cells towards gradients of rmCXCL1 for 10 min. 
(A) Representative exemplary single cell migration tracks and (B) Rose plots. Triangles 
indicate orientation of gradients. (C) Migration velocity and Euclidean distance, as well as 
directness and forward migration index (x) (FMI). Mean ± SEM, n = 4 (503 Myh9-KD and 
320 Myh9-RES dHoxb8 cells). n.s. not significant, * p < 0.05 (adapted from Zehrer et al., 
2018180). 
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3.4.4 Role of Myh9 during 3D migration 
To elucidate the role of Myh9 during 3D migration in collagen meshwork towards a 
chemotactic gradient of rmCXCL1, the spatial and temporal dynamics of Myh9 were analysed 
using live-cell spinning disk confocal microscopy of Myh9-EGFP expressing Myh9-RES 
dHoxb8 cells. First, differences in Myh9 localisation during fast, medium, and slow migration 
were investigated.  
 
 
Figure 33. Myh9-EGFP distribution during different migration speeds in 3D 
environment. Upper panel: Relative distribution of Myh9 to the front and back of Myh9-RES 
dHoxb8 cells compared to whole cell intensity of Myh9-EGFP (100%) during fast, medium, 
or slow migration. Cell area was equally split into front and back (n=23 for fast migration, 
n=17 for medium migration, n=28 for slow migration). Middle and lower panel: 
Representative fast, medium, and slow migrating cells with Myh9 in pseudocolours and 
intensity profile along segmented line (adapted from Zehrer et al., 2018180). 
 
The fastest, a medium, and the slowest migration velocity were detected for each individual 
cell and the intracellular localisation of Myh9 was analysed at these three time points 
(Fig. 33). Fast migrating Myh9-RES dHoxb8 cells displayed a mean velocity of 5.5 ± 0.6 
μm/min and localised Myh9 mainly towards the rear of the cell. Myh9-RES dHoxb8 cells 
migrating with a medium migration velocity of 3.3 ± 0.2 μm/min located Myh9-EGFP equally 
to the front and the back of the cell180. Slow migrating Myh9-RES dHoxb8 cells with a 
velocity of 1.8 ± 0.2 μm/min positioned Myh9 more to the front of the cell. This analysis was 
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visualised based on one representative fast, one medium, and one slow migrating cell using 
Myh9 intensity profiling along a horizontal axis through the cell (Fig. 33 lower panel).  
 
 
Figure 34. Myh9-EGFP specifically localised at sites of cell membrane retraction during 
3D migration. (A) Representative pseudocoloured snapshots at indicated time points during 
3D migration of Myh9-RES dHoxb8 cells demonstrating the subcellular localisation of Myh9. 
Triangles indicate orientation of gradients. Arrow indicates direction of migration, 
arrowheads point towards retracting membrane sites. Scale bar, 5 µm. (B) Model of Myh9 
localisation and function during migration: retraction of branching lammelipodia and the 
uropod (adapted from Zehrer et al., 2018180) 
 
Furthermore, the analysis of the recorded videos revealed that Myh9-RES dHox8 cells 
enriched Myh9 in branching lamellipodia and at the rear of the cells while retracting these cell 
compartments (Fig. 34A). Branching lamellipodia were retracted upon the enrichment of 
Myh9, leading to a consolidation of the leading edge towards the chemoattractant. Taken 
together, these findings suggest a model where Myh9 exerts its function specifically at sites of 
membrane retraction for example branching lamellipodia and retraction of the rear of the cell 
(Fig. 34B)180.  
 
In summary, the genetic approach to knock-down Myh9 in the hematopoietic system of mice 
resulted in a reduction of Myh9 expression down to less than 30% in PMN. With his residual 
expression PMN were not able to migrate or to transmigrate as efficient as control PMN in 
vitro. Additionally, the reduced amount of Myh9 was found to influence the subcellular 
localisation of F-actin and Myh9, as well as their interaction strength. The in vitro results 
were confirmed in two in vivo models. Here, the Myh9-cHet PMN displayed reduced 
extravasation and migratory speed compared to control PMN. Using bone marrow chimeric 
mice, a cell-intrinsic defect of PMN with reduced Myh9 expression was identified. Using the 
Hoxb8-SCF cell model and by expression of Myh9-EGFP in Myh9-KD cells, the 
spatiotemporal distribution of Myh9 during migration was elucidated. 
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4 Discussion 
In the past, studies on the functional impact of Myh9 in polymorphonuclear neutrophils 
(PMN) have been limited to pharmacological inhibitors. In this study, a genetic approach to 
knock-down Myh9 in PMN was applied using Vav-iCre+/Myh9wt/fl (Myh9-cHet) mice. 
Furthermore, a Myh9 knock-down Hoxb8-SCF cell line and a cell line expressing rescuing 
Myh9-EGFP were established. The data demonstrated the importance of Myh9 for 2D 
migration, transmigration, and 3D migration in vitro. Using STED nanoscopy, dysregulation 
of F-actin and Myh9 dynamics were found upon Myh9 downregulation. In vivo, PMN with a 
downregulation of Myh9 demonstrated defects in extravasation and interstitial migration in 
two different models, the CXCL1-induced peritonitis model and a laser-induced injury model 
in the ear. Bone marrow chimeras confirmed the cell-intrinsic migration defect of PMN with a 
downregulation in Myh9. The versatile subcellular localisation of Myh9 and its role in 
membrane retraction during migration were elucidated using live cell imaging180.  
 
4.1 Effect of pharmacological inhibition of class II non-muscle myosin on 
PMN migration 
In the first part of the study, PMN isolated from the bone marrow of wildtype mice were 
treated with pn-blebbistatin. This cell-permeable compound works as an non-competitive 
inhibitor of the ATPase activity of class II myosins and was developed to eliminate the photo- 
and cytotoxic side effects of the previously used pharmacological inhibitor blebbistatin173,174. 
Previous studies were performed under static conditions in vitro. Therefore, it remained to be 
explored whether the published results reflect the situation under flow conditions mimicking 
the physiological conditions in vivo. In the present study, inhibition of Myh9 had no effect on 
the number of rolling and adherent cells during induction of adhesion under flow 
conditions180. These results were in line with reports for T cells and indicated that Myh9 was 
dispensable for the induction of adhesion of PMN under these conditions159. During 2D 
migration under flow conditions, pn-blebbistatin-treated PMN exhibited a phenotype with 
multiple pseudopods and an elongated uropod as well as reduced migration speed and 
Euclidian distance. These findings were in accordance with results under static conditions 
which also observed a diminished migration speed and the elongated cell shape93,94,178. Both, 
the migration velocity and the elongated phenotype were demonstrated to depend on the 
concentration of pn-blebbistatin. This corresponds well with reports for migration behaviour 
of blebbistatin-treated human umbilical vein endothelial cells, smooth muscle cells and 
macrophages, which also described a dose-dependent effect of blebbistatin on migration196,199. 
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In the present study, spreading of pn-blebbistatin-treated PMN resulted in an increased cell 
area compared to control PMN. This observation was in line with the findings of Jacobelli et 
al. in blebbistatin-treated T cells160. Consistent with other studies showing that blebbistatin-
treated HL-60 cells or T cells failed to properly transmigrate through a monolayer of 
endothelial cells, pn-blebbistatin-treated PMN demonstrated inhibited transmigration146,158. In 
contrast to those studies analysing trans-endothelial migration, in the present work, a 
reductionist transmigration set-up using pn-blebbistatin-treated PMN and a rmICAM-1 coated 
polycarbonate membrane was employed to study transmigration. Also, pn-blebbistatin-treated 
PMN were able to deform and insert their nuclei into the pores of the membrane (data not 
shown), which is in line with previous reports for blebbistatin-treated PMN. However, 
transmigrating T cells were reported to fail in squeezing their nuclei between endothelial cells 
upon blebbistatin treatment146,158, emphasising the necessity to study the distinct roles of 
Myh9 in each specific cell type.  
 
4.2  Impact of Myh9 downregulation on PMN migration 
To specifically knock-out Myh9 in the hematopoietic system, the Vav-iCre system and 
Myh9fl/fl mice were used. As none of the living offspring had the desired Vav-iCre+/Myh9fl/fl 
genotype, the theory that the deletion of Myh9 in the progenitor cells of the hematopoietic 
system is lethal during embryogenesis, was established. This was in accordance with reports 
of Shin et al. using an inducible Myh9 knock-out in bone marrow chimeras. Upon Myh9 
deletion, progenitor cells in the bone marrow stopped dividing and performed progressive 
apoptosis, causing a drop in peripheral blood cells144. In the Vav-iCre mouse model, Cre 
recombinase is active from day E11.5 in all progenitor cells of leukocytes, erythrocytes, and 
in megakaryocytes resulting in a knock-out of Myh9 in these cells179,180,200,201. Based on this 
knowledge, it is likely that Vav-iCre+/Myh9fl/fl foeti died due to a lack of blood cells, as a 
consequence of missing bone marrow progenitor cells. Nevertheless, Vav-iCre+/Myh9wt/fl 
(Myh9-cHet) mice with one Myh9 allele still present were viable and demonstrated an 
unexpected low amount of Myh9 protein in their PMN population compared to          
Vav-iCre-/Myh9wt/fl (control) mice. With one allele missing, a reduction of Myh9 to 50% was 
expected, but a reduction of approximately 75% compared to control PMN (100%) was 
detected180. Similar to the observations with pn-blebbistatin-treated PMN, PMN isolated from 
the bone marrow of Myh9-cHet mice exhibited migration defects with reduced migration 
velocity and Euclidean distance on rmICAM-1 coated surfaces and in 3D collagen 
environment. Interestingly, the prominent phenotype with multiple pseudopods and an 
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elongated uropod, seen in 2D migration in pn-blebbistatin-treated PMN as well as in previous 
reports for blebbistatin-treated murine PMN in 3D migration87, was absent in Myh9-cHet 
PMN. In line with the dose-dependent effects of pn-blebbistatin, a dose-dependent effect of 
Myh9 for migration behaviour seems plausible and one could speculate that the residual 
amount of Myh9 was sufficient to prevent the phenotypic failure. Similarly, a dose-dependent 
effect of Kindlin-3 on murine PMN function and a minimal threshold amount of Kindlin-3 for 
survival was observed202. In the present study, the influence of reduced Myh9 expression on 
integrin affinity seemed unlikely, as migration defects of Myh9-cHet PMN occurred, not just 
on 2D surfaces, but also in 3D collagen environment where migration can occur integrin 
independent87. This theory was supported by the results of the adhesion strengthening assay 
under flow conditions. Here, integrins in the high affinity conformation are crucial for 
resisting increasing shear stress rates and no differences between Myh9-cHet and control 
PMN were detected. This finding was in slight contrast to a report for T cells, finding 
increased numbers of adherent Myh9 knock-out T cells over wildtype T cells in vitro and in 
vivo159. This discrepancy could be the consequence of the residual amount of Myh9 in the 
PMN in this present study compared to the complete knock-out of Myh9 in the T cell study. 
In accordance with the results for pn-blebbistatin-treated PMN, as well as published results 
for Myh9 knock-out T cells, Myh9-cHet PMN displayed less efficient transmigration through 
3 µm membrane pores, and 8 µm membrane pores coated with a monolayer of endothelial 
cells, compared to control PMN158. Defects in maturation, potentially contributing to the 
migration defects, were excluded by comparison of extracellular PMN markers and nuclear 
morphology between Myh9-cHet and control PMN. 
The subcellular localisation of F-actin and Myh9 during 2D migration of control and 
Myh9-cHet PMN was investigated to elucidate the mechanisms behind the reduced migratory 
capacity of Myh9-cHet PMN. Here, control PMN showed the well-characterised F-actin 
distribution to the front and rear of the cell94,104,178,187. Myh9 was visualized at the leading 
edge and the uropod of these cells, as described previously for migrating PMN178,203. This 
distribution pattern was significantly changed in Myh9-cHet PMN. Specifically, F-actin was 
no longer accumulated at the leading edge of the cell but enriched at the trailing edge. 
Interestingly, the remaining Myh9 in Myh9-cHet PMN did not distribute equally to the 
previous locations identified in control PMN but concentrated in one spot close to the rear of 
the PMN. These findings were in line with observations of Eddy et al, describing a re-location 
of F-actin and Myh9 out of the lamellipodium and towards the uropod of migrating PMN after 
treatment with BDM178. Also, blebbistatin-treated endothelial cells displayed disorganized 
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F actin structures composed of short F-actin bundles instead of long F-actin fibres140. A 
randomization approach investigating the dependence of F-actin localisation to Myh9 
distribution, revealed that in control PMN, F-actin distributed dependent on Myh9 in the front 
and back of the cell, whereas upon downregulation of Myh9, the interaction strength of 
F-actin/Myh9 dropped significantly in the front of the cell, suggesting disturbed F-actin 
dynamics in the front of migrating PMN due to Myh9 downregulation180.  
In the past, studies investigating the role of Myh9 in PMN were limited to in vitro assays as 
the established pharmacological inhibitors are problematic in systemic application in vivo and 
for live cell imaging173,204. The genetic model of Myh9 knock-down in hematopoietic cells 
permitted in vivo investigations in this study. The similarity between control and Myh9-cHet 
mice in their WBC counts provided the basis for correct evaluation of the in vivo results. In a 
model of laser-induced sterile injury in the skin of the ear, in vivo life-cell imaging revealed 
that Myh9-cHet mice had a drastic reduction in extravasated PMN compared to control mice 
in the observed 40 min after induction of injury. This indicated that PMN with reduced Myh9 
expression extravasated less efficiently than control PMN in vivo. Furthermore, this model 
enabled the assessment of migration velocity in interstitial tissue in vivo of PMN with reduced 
Myh9 expression. Here, the defects observed in 3D collagen environment in vitro were 
confirmed. Myh9-cHet PMN demonstrated a significant decline in migration velocity and 
Euclidean distance in vivo compared to control PMN. This finding was similar to studies in 
mice with Myh9-deficient T cells, showing less intra-lymph node migration compared to 
control T cells77,159. In a second in vivo model, the rmCXCL1-induced peritonitis model, the 
negative consequences of reduced Myh9 on extravasation for PMN were confirmed. In 
accordance with the in vitro findings, significantly less PMN extravasated into the peritoneum 
in Myh9-cHet mice compared to control mice, highlighting the importance of Myh9 for PMN 
recruitment to sites of inflammation during acute inflammation.  
To test whether these observed effects were due to a cell-intrinsic defect in PMN with reduced 
Myh9, or if other hematopoietic cells with a reduction in Myh9 expression influence the 
PMN, mixed bone marrow chimeras from CD45.1 wildtype and CD45.2 Myh9-cHet mice, as 
well as appropriate control chimeras, were generated and rmCXCL1-induced peritonitis was 
performed. The CD45 congenic marker system is a highly utilized technique to track 
hematopoietic cells after bone marrow transplantation and to efficiently distinguish between 
donor and recipient cells194,205. Since both, donor and recipient cells, develop in the same 
environment, any defects in differentiation or function indicate a cell-intrinsic defect194,205,206. 
Successful engraftment of the bone marrow was verified by analysis WBC counts between 
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WT→WT, HET→WT, and MIX→WT chimeras. The distribution of CD45.1 and CD45.2 
was found as expected confirming the depletion of recipient bone marrow and demonstrating 
that bone marrow cells from Myh9-cHet mice had no disadvantage in repopulating the host 
bone marrow or to contribute to the blood leukocyte pool. The evaluation of the peritoneal 
lavage, 4 h after rmCXCL1 application, revealed similar diminished extravasation in the 
HET→WT, and MIX→WT chimeras compared to the WT→WT control bone marrow 
chimeras. The reduced extravasation in the HET→WT model verified the results observed in 
Myh9-cHet mice and excluded an influence of Cre activity in other than hematopoietic cells. 
The unexpected reduction of extravasated PMN in the MIX→WT chimeras indicated a 
cell-intrinsic defect of PMN with reduced Myh9 expression, as the presence of CD45.1 
wildtype PMN could not rescue the observed extravasation defect. The distribution of CD45.1 
and CD45.2 expressing PMN in the peritoneal lavage was unchanged compared to the 
distribution determined in the blood before the start of the experiment. In combination with 
the reduced numbers of extravasated PMN in the MIX→WT model, a dominant negative 
jamming effect of the Myh9-cHet PMN was hypothesized. Here, the Myh9-cHet-derived PMN 
could block the passages for the wildtype PMN so that wildtype PMN can’t exhaust their 
potential for extravasation. In summary, these results indicate a cell-intrinsic migration defect 
of the Myh9-cHet PMN and that these cells potentially influence the transmigration behaviour 
of wildtype PMN negatively180.  
 
4.3 Hoxb8–SCF cell-derived neutrophils as a valid tool to study PMN 
trafficking 
To perform essential rescue experiments, the Hoxb8-SCF cell system should be applied197,198. 
In the present study, the differentiation of Hoxb8-SCF cells to Hoxb8-SCF cell-derived 
neutrophils (dHoxb8 cells) was optimized for d4. Longer differentiation options were 
dismissed, as the expression of CD11b and CXCR2 were already induced at d4 and the 
percentage of living cells drastically dropped after d4, resulting in increasing amounts of dead 
cells with potential negative effects on surviving cells. The phenotype of undifferentiated 
Hoxb8-SCF cells and dHoxb8 cell was analysed and dHoxb8 cells were discovered to have a 
very similar appearance to murine bone marrow-derived PMN. To apply these dHoxb8 cells 
as a tool to study PMN trafficking, these cells needed to behave similarly to PMN. Hence, 
their response upon stimulation regarding integrin upregulation, induction of adhesion under 
static and flow conditions, migration under flow conditions, as well as chemotaxis was tested. 
Interestingly, even undifferentiated Hoxb8-SCF cells were able to bind to rmICAM-1 under 
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static conditions, due to their constitutive expression of LFA-1, when stimulated with PMA 
and TNFα, but not with the PMN activators rmCXCL1 and fMIVIL. Unexpectedly, dHoxb8 
cells stimulated with TNFα seemed to fail to adhere on mfibrinogen coated surfaces. 
However, under physiological conditions, TNFα operates as an activator of endothelial cells, 
acting mostly indirect on PMN23,25,53. Therefore, the stimulation time of 5 min given to the 
dHoxb8 cells to adhere, may not have been long enough to induce sufficient Mac-1 
upregulation and activation.  
Importantly, under flow conditions, dHoxb8 cells adhered as efficiently as PMN to 
rmICAM-1 coated surfaces upon stimulation with immobilised rmCXCL1. Of particular 
importance was the ability of dHoxb8 cells to sense and orientate to a chemotactic gradient 
and the observation that dHoxb8 cells were able to migrate under flow conditions 
perpendicular to, against and with the direction of flow. Notably, their migration velocity was 
slower compared to PMN. This may be due to their increased cell area in contact with the 
surface compared to PMN, which may cause increased adhesion force. In summary, the 
analysis in functional assays and their phenotypic similarity to murine bone marrow-derived 
PMN, demonstrated the potential of dHoxb8 cells to serve as a useful tool to study processes 
like PMN activation and trafficking. 
 
4.4 Myh9 enrichment at sites of cell membrane retraction 
To ensure the same genetic background for the Hoxb8-SCF cells as in the mice used for the 
performed in vitro and in vivo experiments, Hoxb8-SCF cells were generated from E13 foeti 
of a Vav-iCre+/Myh9wt/fl, Vav-iCre-/Myh9fl/fl breeding pair. Interestingly, at this day during 
embryogenesis, just before the onset of the shift of the definite haematopoiesis from the foetal 
liver to the bone marrow, viable foeti with a Vav-iCre+/Myh9fl/fl genotype were discovered. 
Hence, Hoxb8-SCF cells from foetal liver progenitor cells of Vav-iCre-/Myh9fl/fl, 
Vav-iCre+/Myh9wt/fl and Vav-iCre+/Myh9fl/fl foeti were generated. 
During the establishment of the cell lines, half of the generated Vav-iCre+/Myh9fl/fl 
Hoxb8-SCF cell lines stopped dividing and died (data not shown). The surviving cell lines 
expressed Myh9 comparable to the Hoxb8-SCF cells generated from Vav-iCre+/Myh9wt/fl and 
Vav-iCre-/Myh9fl/fl foetal livers, leading to the theory that only cells with a certain amount of 
Myh9 survived the multiple cell divisions. This theory is in line with previous reports for 
T cells, megakaryocytes and hematopoietic progenitor cells. Specifically, T cell specific 
knock-out of Myh9 led to defects in cell division resulting in multi-nucleated cells and 
increased cell death of T cells158,159. Megakaryocytes with inhibited NMII activity displayed 
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enhanced polyploidy compared to control megakaryocytes and treatment of CD34+ common 
potent progenitor cells with blebbistatin caused cytokinesis-associated cell death of these 
cells144,207.  
Upon differentiation towards PMN, differences in the Myh9 expression between the 
Vav iCre+/Myh9wt/fl (Myh9-cHet), Vav-iCre+/Myh9fl/fl and Vav-iCre-/Myh9fl/fl (control) 
Hoxb8-SCF cells were uncovered using the western blot technique. The reported upregulation 
of Myh9 during the differentiation towards PMN only occurred in control but not in 
Myh9-cHet and Vav-iCre+/Myh9fl/fl Hoxb8-SCF cells144,172. Vav-iCre+/Myh9fl/fl Hoxb8-SCF 
cells were therefore defined as Myh9-knock-down (KD) cells. Flow cytometry analysis of 
intracellularly stained Myh9 confirmed the similar downregulation of Myh9 in Myh9-cHet 
and Myh9-KD compared to control dHoxb8 cells. Furthermore, evaluation of the histograms 
revealed a homogeneous expression of Myh9 within dHoxb8 cells of all three genotypes, 
excluding heterogeneity within the single Hoxb8-SCF cell population. 
To gain further insight into the underlying genetic processes leading to this unexpected Myh9 
expression in Myh9-KD dHoxb8-SCF cells, two genotyping PCR strategies were applied. 
These demonstrated that in Myh9-cHet Hoxb8-SCF cells the Myh9fl allele was deleted in all 
cells by the Cre recombinase under the Vav promotor, as expected for hematopoietic cells. 
Strikingly, Myh9-KD Hoxb8-SCF cells deleted one Myh9fl allele, yet kept the other Myh9fl 
allele. These observations manifested the theory that the high selection pressure to 
successfully perform cell division, during establishment of the cell line and differentiation 
towards PMN, favoured cells with a less active Cre recombinase resulting in Myh9-KD 
Hoxb8-SCF cells with a heterozygous phenotype instead of a knock-out of Myh9. However, 
expression of Ly6G, CXCR2 and CD11b was assessed by flow cytometry and confirmed the 
similar maturity of Myh9-cHet, Myh9-KD and control dHoxb8 cells.  
Analysis of migration behaviour revealed that Myh9-KD dHoxb8 cells had impaired migration 
with reduced migration velocity as well as diminished Euclidean distance, on rmICAM-1 
coated 2D surfaces and in 3D collagen networks, compared to control dHoxb8 cells. These 
results were in line with the findings for Myh9-cHet and control PMN. Importantly, the 
expression of an EGFP-tagged Myh9 fusion protein in the Myh9-KD Hoxb8-SCF cells 
(Myh9-RES Hoxb8-SCF cells) rescued the migratory defects in 2D and 3D environment. 
These results indicated that the observed migration defects in Myh9-cHet PMN and dHoxb8 
cells was specifically caused by a decreased Myh9 expression.  
Using live-cell imaging of Myh9-RES dHoxb8 cells migrating in 3D environment, 
Myh9-EGFP was observed to be enriched at the uropod of fast migrating cells and 
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accumulated in branching lamellipodia. In previous studies, Myh9 was found to be of 
importance to maintain membrane tension but negligible for the formations of 
protrusions87,177. Hence, it seems likely that Myh9 enrichment facilitates membrane retraction. 
This concept corresponds well to the present and previous studies observing elongated tails 
and multiple pseudopods upon blebbistatin treatment during 2D migration, demonstrating the 
lack of Myh9 function in these regions93,94,178. For chemotactic 3D migration this study 
proposed a model in which PMN employ Myh9-dependent membrane retraction to enable fast 
migration by retraction of their uropod, and also to retract branching lamellipodia180. During 
orientation towards a chemoattractant movement of PMN in this direction is promoted by the 
accumulation of Myh9 in one branching lamellipodium and subsequent retraction of the 
branching lamellipodium to consolidate the leading edge in the direction of the 
chemoattractant.  
Together with the Myh9-downregulation-dependent displacement of the acto-myosin network 
out of the lamellipodium to the rear of the cell, as confirmed by the randomisation approach, 
this concept can also be applied to explain the slow migrating phenotype of PMN with 
diminished Myh9 expression. The concentration of the remaining Myh9 at the back of the cell 
could prevent the uropod retraction defect and the diminished F-actin in the lamellipodium 
possibly hampers promotion of forward protrusions resulting in an overall reduced migration 
velocity180.  
This present study demonstrates the generic importance of Myh9 for PMN migration. A 
remaining Myh9 expression of less than 30% was not sufficient for murine bone marrow-
derived PMN to perform proper migration in 2D or 3D environment or to transmigrate. 
Investigations of the underlying mechanisms revealed that maintenance of proper F-actin 
dynamics in the front of the migrating cell required a certain threshold amount of Myh9. The 
defect in extravasation was also observed in a model of laser-induced sterile injury in the ear 
and in a rmCXCL1-induced peritonitis using Myh9-cHet and control mice, indicating the 
relevance of Myh9 in vivo. Bone marrow chimeric mice confirmed the cell-intrinsic migration 
defect of PMN with reduced Myh9. Rescuing Myh9 expression enabled Myh9-RES dHoxb8 
cells to increase their migration velocity and Euclidean distance to control levels180. Taken 
together, this study proved that the non-muscle myosin heavy chain Myh9 is essential for 
PMN migration during acute inflammation. 
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